{"context": "The COVID-19 pandemic also known as the coronavirus pandemic and COVID pandemic caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 began with an outbreak of COVID-19 in Wuhan China in December 2019\nSoon after it spread to other areas of Asia and then worldwide in early 2020\nThe World Health Organization WHO declared the outbreak a public health emergency of international concern PHEIC on 30 January 2020 and assessed the outbreak as having become a pandemic on 11 March", "evidence": "An outbreak of COVID-19 in China began in December of 2019.\nIn early 2020 it spread to other areas of Asia.\nThe outbreak was declared a public health emergency of international concern by the World Health Organization on January 30, 2020 and was assessed as having become a Pandemic on March 11, 2020.", "einfo": {"ss": [0.28, 0.78, 0.55], "cs": [1.0], "pv": [["China in December"], [], []], "uv": [["Wuhan China", "respiratory syndrome coronavirus"], ["worldwide in early"], ["Organization WHO declared", "international concern PHEIC"]]}, "hf": 0}
{"context": "The COVID-19 pandemic also known as the coronavirus pandemic and COVID pandemic caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 began with an outbreak of COVID-19 in Wuhan China in December 2019\nSoon after it spread to other areas of Asia and then worldwide in early 2020\nThe World Health Organization WHO declared the outbreak a public health emergency of international concern PHEIC on 30 January 2020 and assessed the outbreak as having become a pandemic on 11 March", "evidence": "An outbreak of COVID-19 in China began in December of 2019.\nIn early 2020 it spread to other areas of Asia.\nThe outbreak was declared a public health emergency of international concern by the World Health Organization on January 30, 2020 and was assessed as having become a Pandemic on March 11, 2020.", "einfo": {"ss": [0.28, 0.78, 0.55], "cs": [1.0], "pv": [["China in December"], [], []], "uv": [["Wuhan China", "respiratory syndrome coronavirus"], ["worldwide in early"], ["Organization WHO declared", "international concern PHEIC"]]}, "hf": 0}
{"context": "The World Health Organization WHO declared the outbreak a public health emergency of international concern PHEIC on 30 January 2020 and assessed the outbreak as having become a pandemic on 11 March\nCOVID-19 symptoms range from asymptomatic to deadly but most commonly include fever sore throat nocturnal cough and fatigue", "evidence": "The outbreak was declared a public health emergency of international concern by the World Health Organization on January 30, 2020 and was assessed as having become a Pandemic on March 11, 2020.\nCovid-19 symptoms include a sore throat, cough and fatigue.", "einfo": {"ss": [0.55, 0.62], "cs": [1.0], "pv": [[], ["sore throat nocturnal", "include fever sore"]], "uv": [["Organization WHO declared", "international concern PHEIC"], ["symptoms range"]]}, "hf": 0}
{"context": "COVID-19 symptoms range from asymptomatic to deadly but most commonly include fever sore throat nocturnal cough and fatigue\nTransmission of the virus is often through airborne particles\nMutations have produced many strains variants with varying degrees of infectivity and virulence", "evidence": "Covid-19 symptoms include a sore throat, cough and fatigue.\nThe virus can be transmitted through particles.\nDifferent strains have been produced with different degrees of virulence.", "einfo": {"ss": [0.62, 0.29, 0.32], "cs": [1.0], "pv": [["sore throat nocturnal", "include fever sore"], [], ["degrees of infectivity"]], "uv": [["symptoms range"], ["virus is often", "airborne particles"], ["varying degrees", "produced many strains", "Mutations have produced"]]}, "hf": 0}
{"context": "COVID-19 vaccines were developed rapidly and deployed to the general public beginning in December 2020 made available through government and international programmes such as COVAX aiming to provide vaccine equity\nTreatments include novel antiviral drugs and symptom control\nCommon mitigation measures during the public health emergency included travel restrictions lockdowns business restrictions and closures workplace hazard controls mask mandates quarantines testing systems and contact tracing of the infected\nThe pandemic caused severe social and economic disruption around the world including the largest global recession since the Great Depression", "evidence": "The general public will be able to receive the COVID-19 vaccines in December 2020 through government and international programmes.\nNovel drugs and symptom control are included in the treatments.\nTravel restrictions, business restrictions, and workplace hazard controls were some of the common measures taken during the public health emergency.\nThe global recession is the largest since the Great Depression and was caused by the Pandemic.", "einfo": {"ss": [0.27, 0.72, 0.55, 0.65], "cs": [1.0], "pv": [["general public beginning", "beginning in December"], ["novel antiviral drugs"], ["Common mitigation measures"], ["largest global recession"]], "uv": [["rapidly and deployed", "provide vaccine equity", "developed rapidly"], ["Treatments include novel"], ["emergency included travel", "mandates quarantines testing"], ["pandemic caused severe", "global recession since"]]}, "hf": 0}
{"context": "COVID-19 vaccines were developed rapidly and deployed to the general public beginning in December 2020 made available through government and international programmes such as COVAX aiming to provide vaccine equity\nTreatments include novel antiviral drugs and symptom control\nCommon mitigation measures during the public health emergency included travel restrictions lockdowns business restrictions and closures workplace hazard controls mask mandates quarantines testing systems and contact tracing of the infected\nThe pandemic caused severe social and economic disruption around the world including the largest global recession since the Great Depression", "evidence": "The general public will be able to receive the COVID-19 vaccines in December 2020 through government and international programmes.\nNovel drugs and symptom control are included in the treatments.\nTravel restrictions, business restrictions, and workplace hazard controls were some of the common measures taken during the public health emergency.\nThe global recession is the largest since the Great Depression and was caused by the Pandemic.", "einfo": {"ss": [0.27, 0.72, 0.55, 0.65], "cs": [1.0], "pv": [["general public beginning", "beginning in December"], ["novel antiviral drugs"], ["Common mitigation measures"], ["largest global recession"]], "uv": [["rapidly and deployed", "provide vaccine equity", "developed rapidly"], ["Treatments include novel"], ["emergency included travel", "mandates quarantines testing"], ["pandemic caused severe", "global recession since"]]}, "hf": 0}
{"context": "Common mitigation measures during the public health emergency included travel restrictions lockdowns business restrictions and closures workplace hazard controls mask mandates quarantines testing systems and contact tracing of the infected\nThe pandemic caused severe social and economic disruption around the world including the largest global recession since the Great Depression\nWidespread supply shortages including food shortages were caused by supply chain disruptions and panic buying", "evidence": "Travel restrictions, business restrictions, and workplace hazard controls were some of the common measures taken during the public health emergency.\nThe global recession is the largest since the Great Depression and was caused by the Pandemic.\nSupply chain disruptions and panic buying caused widespread food shortages.", "einfo": {"ss": [0.55, 0.65, 0.47], "cs": [1.0], "pv": [["Common mitigation measures"], ["largest global recession"], ["panic buying", "Widespread supply shortages"]], "uv": [["emergency included travel", "mandates quarantines testing"], ["pandemic caused severe", "global recession since"], ["shortages including food", "supply shortages including"]]}, "hf": 0}
{"context": "Common mitigation measures during the public health emergency included travel restrictions lockdowns business restrictions and closures workplace hazard controls mask mandates quarantines testing systems and contact tracing of the infected\nThe pandemic caused severe social and economic disruption around the world including the largest global recession since the Great Depression\nWidespread supply shortages including food shortages were caused by supply chain disruptions and panic buying\nReduced human activity led to an unprecedented temporary decrease in pollution\nEducational institutions and public areas were partially or fully closed in many jurisdictions and many events were cancelled or postponed during 2020 and 2021", "evidence": "Travel restrictions, business restrictions, and workplace hazard controls were some of the common measures taken during the public health emergency.\nThe global recession is the largest since the Great Depression and was caused by the Pandemic.\nSupply chain disruptions and panic buying caused widespread food shortages.\nReduced human activity resulted in a decrease in pollution.\nDuring 2020 and 2021, many educational institutions and public areas were partially or fully closed.", "einfo": {"ss": [0.55, 0.65, 0.47, 0.83, 0.94], "cs": [1.0], "pv": [["Common mitigation measures"], ["largest global recession"], ["panic buying", "Widespread supply shortages"], ["human activity led"], ["Educational institutions"]], "uv": [["emergency included travel", "mandates quarantines testing"], ["pandemic caused severe", "global recession since"], ["shortages including food", "supply shortages including"], [], []]}, "hf": 0}
{"context": "The pandemic caused severe social and economic disruption around the world including the largest global recession since the Great Depression\nWidespread supply shortages including food shortages were caused by supply chain disruptions and panic buying\nReduced human activity led to an unprecedented temporary decrease in pollution\nEducational institutions and public areas were partially or fully closed in many jurisdictions and many events were cancelled or postponed during 2020 and 2021\nTelework became much more common for white-collar workers as the pandemic evolved", "evidence": "The global recession is the largest since the Great Depression and was caused by the Pandemic.\nSupply chain disruptions and panic buying caused widespread food shortages.\nReduced human activity resulted in a decrease in pollution.\nDuring 2020 and 2021, many educational institutions and public areas were partially or fully closed.\nWhite-collar workers were more likely to work telework.", "einfo": {"ss": [0.65, 0.47, 0.83, 0.94, 0.42], "cs": [1.0], "pv": [["largest global recession"], ["panic buying", "Widespread supply shortages"], ["human activity led"], ["Educational institutions"], []], "uv": [["pandemic caused severe", "global recession since"], ["shortages including food", "supply shortages including"], [], [], ["Telework became much", "common for white-collar"]]}, "hf": 0}
{"context": "Reduced human activity led to an unprecedented temporary decrease in pollution\nEducational institutions and public areas were partially or fully closed in many jurisdictions and many events were cancelled or postponed during 2020 and 2021\nTelework became much more common for white-collar workers as the pandemic evolved", "evidence": "Reduced human activity resulted in a decrease in pollution.\nDuring 2020 and 2021, many educational institutions and public areas were partially or fully closed.\nWhite-collar workers were more likely to work telework.", "einfo": {"ss": [0.83, 0.94, 0.42], "cs": [1.0], "pv": [["human activity led"], ["Educational institutions"], []], "uv": [[], [], ["Telework became much", "common for white-collar"]]}, "hf": 0}
{"context": "Telework became much more common for white-collar workers as the pandemic evolved\nMisinformation circulated through social media and mass media and political tensions intensified", "evidence": "White-collar workers were more likely to work telework.\nPolitical tensions and misinformation spread through social media.", "einfo": {"ss": [0.42, 0.54], "cs": [1.0], "pv": [[], ["political tensions intensified", "circulated through social"]], "uv": [["Telework became much", "common for white-collar"], ["Misinformation circulated", "media and political"]]}, "hf": 0}
{"context": "Misinformation circulated through social media and mass media and political tensions intensified\nThe pandemic raised issues of racial and geographic discrimination health equity and the balance between public health imperatives and individual rights\nThe WHO ended the PHEIC for COVID-19 on 5 May 2023", "evidence": "Political tensions and misinformation spread through social media.\nIssues of racial and geographic discrimination health equity and the balance between public health imperatives and individual rights were raised by the Pandemic.\nOn May 5, 2023, the WHO ended the PHEIC.", "einfo": {"ss": [0.54, 0.83, 1.0], "cs": [1.0], "pv": [["political tensions intensified", "circulated through social"], [], []], "uv": [["Misinformation circulated", "media and political"], ["pandemic raised issues"], []]}, "hf": 0}
{"context": "The disease has continued to circulate\nHowever as of 2024 experts were uncertain as to whether it was still a pandemic\nPandemics and their ends are not well-defined and whether or not one has ended differs according to the definition used\nAs of 1 April 2025 COVID-19 has caused 7057132 confirmed deaths and 182 to 335 million estimated deaths\nThe COVID-19 pandemic ranks as the fifth-deadliest pandemic or epidemic in history", "evidence": "The disease has not stopped.\nExperts were unsure as to whether or not it was still a disease.\nAccording to the definition used, pandemics and their ends are not well-defined.\n7057132 deaths and 182 to 335 million deaths have been caused by COVID-19.\nIt is the fifth-deadliest epidemic in history.", "einfo": {"ss": [0.17, 0.5, 0.71, 0.83, 0.75], "cs": [1.0], "pv": [[], ["experts were uncertain", "still a pandemic"], ["well-defined and whether"], ["million estimated deaths"], ["fifth-deadliest pandemic"]], "uv": [["disease has continued", "continued to circulate"], [], ["ended differs according"], [], []]}, "hf": 0}
{"context": "However as of 2024 experts were uncertain as to whether it was still a pandemic\nPandemics and their ends are not well-defined and whether or not one has ended differs according to the definition used\nAs of 1 April 2025 COVID-19 has caused 7057132 confirmed deaths and 182 to 335 million estimated deaths\nThe COVID-19 pandemic ranks as the fifth-deadliest pandemic or epidemic in history", "evidence": "Experts were unsure as to whether or not it was still a disease.\nAccording to the definition used, pandemics and their ends are not well-defined.\n7057132 deaths and 182 to 335 million deaths have been caused by COVID-19.\nIt is the fifth-deadliest epidemic in history.", "einfo": {"ss": [0.5, 0.71, 0.83, 0.75], "cs": [1.0], "pv": [["experts were uncertain", "still a pandemic"], ["well-defined and whether"], ["million estimated deaths"], ["fifth-deadliest pandemic"]], "uv": [[], ["ended differs according"], [], []]}, "hf": 0}
{"context": "The COVID-19 pandemic ranks as the fifth-deadliest pandemic or epidemic in history\n Terminology  Pandemic In epidemiology a pandemic is defined as an epidemic occurring over a very wide area crossing international boundaries and usually affecting a large number of people\nDuring the COVID-19 pandemic as with other pandemics the meaning of this term has been challenged", "evidence": "It is the fifth-deadliest epidemic in history.\nPandemic is defined as an epidemic occurring over a wide area crossing international boundaries and affecting a lot of people.\nThe meaning of this term has been challenged during the COVID-19 Pandemic.", "einfo": {"ss": [0.75, 0.79, 0.44], "cs": [1.0], "pv": [["fifth-deadliest pandemic"], ["number of people"], []], "uv": [[], ["Terminology Pandemic"], ["pandemics the meaning", "challenged"]]}, "hf": 0}
{"context": "Terminology  Pandemic In epidemiology a pandemic is defined as an epidemic occurring over a very wide area crossing international boundaries and usually affecting a large number of people\nDuring the COVID-19 pandemic as with other pandemics the meaning of this term has been challenged\nThe end of a pandemic or other epidemic only rarely involves the total disappearance of a disease and historically much less attention has been given to defining the ends of epidemics than their beginnings\nThe ends of particular epidemics have been defined in a variety of ways differing according to academic field and differently based on location and social group\nAn epidemics end can be considered a social phenomenon not just a biological one", "evidence": "Pandemic is defined as an epidemic occurring over a wide area crossing international boundaries and affecting a lot of people.\nThe meaning of this term has been challenged during the COVID-19 Pandemic.\nHistorically less attention has been given to defining the ends of epidemics than their beginnings, and the end of a Pandemic only rarely involves the total disappearance of a disease.\nThere are different ways in which the ends of epidemics have been defined, depending on location and social group.\nThe end of an epidemic can be considered a social phenomenon.", "einfo": {"ss": [0.79, 0.44, 0.35, 0.33, 0.83], "cs": [1.0], "pv": [["number of people"], [], ["historically much less"], ["ends of particular"], ["epidemics end"]], "uv": [["Terminology Pandemic"], ["pandemics the meaning", "challenged"], ["rarely involves", "disease and historically", "much less attention"], ["ways differing according", "field and differently", "according to academic", "particular epidemics"], []]}, "hf": 0}
{"context": "During the COVID-19 pandemic as with other pandemics the meaning of this term has been challenged\nThe end of a pandemic or other epidemic only rarely involves the total disappearance of a disease and historically much less attention has been given to defining the ends of epidemics than their beginnings\nThe ends of particular epidemics have been defined in a variety of ways differing according to academic field and differently based on location and social group\nAn epidemics end can be considered a social phenomenon not just a biological one", "evidence": "The meaning of this term has been challenged during the COVID-19 Pandemic.\nHistorically less attention has been given to defining the ends of epidemics than their beginnings, and the end of a Pandemic only rarely involves the total disappearance of a disease.\nThere are different ways in which the ends of epidemics have been defined, depending on location and social group.\nThe end of an epidemic can be considered a social phenomenon.", "einfo": {"ss": [0.44, 0.35, 0.33, 0.83], "cs": [1.0], "pv": [[], ["historically much less"], ["ends of particular"], ["epidemics end"]], "uv": [["pandemics the meaning", "challenged"], ["rarely involves", "disease and historically", "much less attention"], ["ways differing according", "field and differently", "according to academic", "particular epidemics"], []]}, "hf": 0}
{"context": "The ends of particular epidemics have been defined in a variety of ways differing according to academic field and differently based on location and social group\nAn epidemics end can be considered a social phenomenon not just a biological one", "evidence": "There are different ways in which the ends of epidemics have been defined, depending on location and social group.\nThe end of an epidemic can be considered a social phenomenon.", "einfo": {"ss": [0.33, 0.83], "cs": [1.0], "pv": [["ends of particular"], ["epidemics end"]], "uv": [["ways differing according", "field and differently", "according to academic", "particular epidemics"], []]}, "hf": 0}
{"context": "The ends of particular epidemics have been defined in a variety of ways differing according to academic field and differently based on location and social group\nAn epidemics end can be considered a social phenomenon not just a biological one\nTime reported in March 2024 that expert opinions differ on whether or not COVID-19 is currently considered endemic or pandemic and that the WHO continued to call the disease a pandemic on its website\n Virus names During the initial outbreak in Wuhan the virus and disease were commonly referred to as coronavirus Wuhan coronavirus the coronavirus outbreak and the Wuhan coronavirus outbreak with the disease sometimes called Wuhan pneumonia\nIn January 2020 the WHO recommended 2019-nCoV and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 international guidelines against using geographical locations eg", "evidence": "There are different ways in which the ends of epidemics have been defined, depending on location and social group.\nThe end of an epidemic can be considered a social phenomenon.\nThe WHO continued to call the disease a Pandemic even after expert opinions differed on whether or not it is currently endemic.\nThe coronaviruses outbreak and the Wuhan coronaviruses outbreak were commonly referred to as coronaviruses.\nThe World Health Organization recommended in January 2020 to use interim names for the virus and disease in order to comply with international guidelines.", "einfo": {"ss": [0.33, 0.83, 0.44, 0.17, 0.17], "cs": [1.0], "pv": [["ends of particular"], ["epidemics end"], ["currently considered endemic"], ["Wuhan coronavirus outbreak"], ["interim names"]], "uv": [["ways differing according", "field and differently", "according to academic", "particular epidemics"], [], ["reported in March", "differ on whether", "Time reported"], ["coronavirus Wuhan coronavirus", "disease sometimes called"], ["using geographical locations", "acute respiratory disease", "international guidelines"]]}, "hf": 0}
{"context": "Time reported in March 2024 that expert opinions differ on whether or not COVID-19 is currently considered endemic or pandemic and that the WHO continued to call the disease a pandemic on its website\n Virus names During the initial outbreak in Wuhan the virus and disease were commonly referred to as coronavirus Wuhan coronavirus the coronavirus outbreak and the Wuhan coronavirus outbreak with the disease sometimes called Wuhan pneumonia\nIn January 2020 the WHO recommended 2019-nCoV and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 international guidelines against using geographical locations eg\nWuhan China animal species or groups of people in disease and virus names in part to prevent social stigma", "evidence": "The WHO continued to call the disease a Pandemic even after expert opinions differed on whether or not it is currently endemic.\nThe coronaviruses outbreak and the Wuhan coronaviruses outbreak were commonly referred to as coronaviruses.\nThe World Health Organization recommended in January 2020 to use interim names for the virus and disease in order to comply with international guidelines.\nIn order to prevent social stigma, animal species and groups of people in disease names.", "einfo": {"ss": [0.44, 0.17, 0.17, 0.48], "cs": [1.0], "pv": [["currently considered endemic"], ["Wuhan coronavirus outbreak"], ["interim names"], ["China animal species"]], "uv": [["reported in March", "differ on whether", "Time reported"], ["coronavirus Wuhan coronavirus", "disease sometimes called"], ["using geographical locations", "acute respiratory disease", "international guidelines"], ["people in disease", "Wuhan China animal"]]}, "hf": 0}
{"context": "Virus names During the initial outbreak in Wuhan the virus and disease were commonly referred to as coronavirus Wuhan coronavirus the coronavirus outbreak and the Wuhan coronavirus outbreak with the disease sometimes called Wuhan pneumonia\nIn January 2020 the WHO recommended 2019-nCoV and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 international guidelines against using geographical locations eg\nWuhan China animal species or groups of people in disease and virus names in part to prevent social stigma\nWHO finalised the official names COVID-19 and SARS-CoV-2 on 11 February 2020", "evidence": "The coronaviruses outbreak and the Wuhan coronaviruses outbreak were commonly referred to as coronaviruses.\nThe World Health Organization recommended in January 2020 to use interim names for the virus and disease in order to comply with international guidelines.\nIn order to prevent social stigma, animal species and groups of people in disease names.\nOn February 11, 2020, the official names were finalized.", "einfo": {"ss": [0.17, 0.17, 0.48, 0.67], "cs": [1.0], "pv": [["Wuhan coronavirus outbreak"], ["interim names"], ["China animal species"], []], "uv": [["coronavirus Wuhan coronavirus", "disease sometimes called"], ["using geographical locations", "acute respiratory disease", "international guidelines"], ["people in disease", "Wuhan China animal"], ["finalised the official"]]}, "hf": 0}
{"context": "In January 2020 the WHO recommended 2019-nCoV and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 international guidelines against using geographical locations eg\nWuhan China animal species or groups of people in disease and virus names in part to prevent social stigma", "evidence": "The World Health Organization recommended in January 2020 to use interim names for the virus and disease in order to comply with international guidelines.\nIn order to prevent social stigma, animal species and groups of people in disease names.", "einfo": {"ss": [0.17, 0.48], "cs": [1.0], "pv": [["interim names"], ["China animal species"]], "uv": [["using geographical locations", "acute respiratory disease", "international guidelines"], ["people in disease", "Wuhan China animal"]]}, "hf": 0}
{"context": "WHO finalised the official names COVID-19 and SARS-CoV-2 on 11 February 2020\nTedros Adhanom Ghebreyesus explained CO for corona VI for virus D for disease and 19 for when the outbreak was first identified 31 December 2019\nWHO additionally uses the COVID-19 virus and the virus responsible for COVID-19 in public communications", "evidence": "On February 11, 2020, the official names were finalized.\nCO for corona VI and 19 for when the outbreak was first identified were explained by Tedros Adhanom.\nThe COVID-19 virus is used in public communications by the WHO.", "einfo": {"ss": [0.67, 0.57, 0.5], "cs": [1.0], "pv": [[], ["Tedros Adhanom Ghebreyesus"], []], "uv": [["finalised the official"], ["Adhanom Ghebreyesus explained", "December"], ["additionally uses", "virus responsible"]]}, "hf": 0}
{"context": "WHO finalised the official names COVID-19 and SARS-CoV-2 on 11 February 2020\nTedros Adhanom Ghebreyesus explained CO for corona VI for virus D for disease and 19 for when the outbreak was first identified 31 December 2019\nWHO additionally uses the COVID-19 virus and the virus responsible for COVID-19 in public communications\nWHO named variants of concern and variants of interest using Greek letters", "evidence": "On February 11, 2020, the official names were finalized.\nCO for corona VI and 19 for when the outbreak was first identified were explained by Tedros Adhanom.\nThe COVID-19 virus is used in public communications by the WHO.\nGreek letters were used to name the variant of concern and variant of interest.", "einfo": {"ss": [0.67, 0.57, 0.5, 0.59], "cs": [1.0], "pv": [[], ["Tedros Adhanom Ghebreyesus"], [], ["named variants", "using Greek letters"]], "uv": [["finalised the official"], ["Adhanom Ghebreyesus explained", "December"], ["additionally uses", "virus responsible"], ["interest using Greek", "concern and variants"]]}, "hf": 0}
{"context": "WHO named variants of concern and variants of interest using Greek letters\nThe initial practice of naming them according to where the variants were identified eg\nDelta began as the Indian variant is no longer common", "evidence": "Greek letters were used to name the variant of concern and variant of interest.\nAccording to where the variants were identified, the initial practice of naming them was done.\nThe Indian variant is no longer used in Delta.", "einfo": {"ss": [0.59, 0.83, 0.62], "cs": [1.0], "pv": [["named variants", "using Greek letters"], [], []], "uv": [["interest using Greek", "concern and variants"], ["naming them according"], ["Delta began"]]}, "hf": 0}
{"context": "WHO named variants of concern and variants of interest using Greek letters\nThe initial practice of naming them according to where the variants were identified eg\nDelta began as the Indian variant is no longer common\nA more systematic naming scheme reflects the variants PANGO lineage eg Omicrons lineage is B11529 and is used for other variants", "evidence": "Greek letters were used to name the variant of concern and variant of interest.\nAccording to where the variants were identified, the initial practice of naming them was done.\nThe Indian variant is no longer used in Delta.\nThe Omicrons lineage is B11529 and is used in a more systematic naming scheme.", "einfo": {"ss": [0.59, 0.83, 0.62, 1.0], "cs": [1.0], "pv": [["named variants", "using Greek letters"], [], [], []], "uv": [["interest using Greek", "concern and variants"], ["naming them according"], ["Delta began"], []]}, "hf": 0}
{"context": "Delta began as the Indian variant is no longer common\nA more systematic naming scheme reflects the variants PANGO lineage eg Omicrons lineage is B11529 and is used for other variants", "evidence": "The Indian variant is no longer used in Delta.\nThe Omicrons lineage is B11529 and is used in a more systematic naming scheme.", "einfo": {"ss": [0.62, 1.0], "cs": [1.0], "pv": [[], []], "uv": [["Delta began"], []]}, "hf": 0}
{"context": "A more systematic naming scheme reflects the variants PANGO lineage eg Omicrons lineage is B11529 and is used for other variants\n Epidemiology  Background SARS-CoV-2 is a virus closely related to bat coronaviruses pangolin coronaviruses and SARS-CoV\nThe first known outbreak the 2019\u20132020 COVID-19 outbreak in mainland China started in Wuhan Hubei China in December 2019", "evidence": "The Omicrons lineage is B11529 and is used in a more systematic naming scheme.\nThe disease is related to bat coronaviruses pangolin coronaviruses and the human immunodeficiency virus.\nThe first known outbreak in mainland China was in December of 2019.", "einfo": {"ss": [1.0, 0.6, 0.62], "cs": [1.0], "pv": [[], [], ["mainland China started"]], "uv": [[], ["virus closely related", "related to bat"], ["China in December"]]}, "hf": 0}
{"context": "A more systematic naming scheme reflects the variants PANGO lineage eg Omicrons lineage is B11529 and is used for other variants\n Epidemiology  Background SARS-CoV-2 is a virus closely related to bat coronaviruses pangolin coronaviruses and SARS-CoV\nThe first known outbreak the 2019\u20132020 COVID-19 outbreak in mainland China started in Wuhan Hubei China in December 2019\nMany early cases were linked to people who had visited the Huanan Seafood Wholesale Market there but it is possible that human-to-human transmission began earlier\nMolecular clock analysis suggests that the first cases were likely to have been between October and November 2019", "evidence": "The Omicrons lineage is B11529 and is used in a more systematic naming scheme.\nThe disease is related to bat coronaviruses pangolin coronaviruses and the human immunodeficiency virus.\nThe first known outbreak in mainland China was in December of 2019.\nIt is possible that human-to-human transmission began earlier because many early cases were linked to people who had visited the Huanan Seafood Wholesale Market.\nThe first cases may have been between October and November.", "einfo": {"ss": [1.0, 0.6, 0.62, 1.0, 0.83], "cs": [1.0], "pv": [[], [], ["mainland China started"], [], ["first cases"]], "uv": [[], ["virus closely related", "related to bat"], ["China in December"], [], []]}, "hf": 0}
{"context": "The first known outbreak the 2019\u20132020 COVID-19 outbreak in mainland China started in Wuhan Hubei China in December 2019\nMany early cases were linked to people who had visited the Huanan Seafood Wholesale Market there but it is possible that human-to-human transmission began earlier\nMolecular clock analysis suggests that the first cases were likely to have been between October and November 2019", "evidence": "The first known outbreak in mainland China was in December of 2019.\nIt is possible that human-to-human transmission began earlier because many early cases were linked to people who had visited the Huanan Seafood Wholesale Market.\nThe first cases may have been between October and November.", "einfo": {"ss": [0.62, 1.0, 0.83], "cs": [1.0], "pv": [["mainland China started"], [], ["first cases"]], "uv": [["China in December"], [], []]}, "hf": 0}
{"context": "The first known outbreak the 2019\u20132020 COVID-19 outbreak in mainland China started in Wuhan Hubei China in December 2019\nMany early cases were linked to people who had visited the Huanan Seafood Wholesale Market there but it is possible that human-to-human transmission began earlier\nMolecular clock analysis suggests that the first cases were likely to have been between October and November 2019", "evidence": "The first known outbreak in mainland China was in December of 2019.\nIt is possible that human-to-human transmission began earlier because many early cases were linked to people who had visited the Huanan Seafood Wholesale Market.\nThe first cases may have been between October and November.", "einfo": {"ss": [0.62, 1.0, 0.83], "cs": [1.0], "pv": [["mainland China started"], [], ["first cases"]], "uv": [["China in December"], [], []]}, "hf": 0}
{"context": "Molecular clock analysis suggests that the first cases were likely to have been between October and November 2019\nThe scientific consensus is that the virus is most likely of a zoonotic origin from bats or another closely related mammal", "evidence": "The first cases may have been between October and November.\nThe virus is most likely a zoonotic origin from bats or another closely related mammal according to the scientific consensus.", "einfo": {"ss": [0.83, 0.67], "cs": [1.0], "pv": [["first cases"], []], "uv": [[], ["origin from bats", "bats or another"]]}, "hf": 0}
{"context": "Molecular clock analysis suggests that the first cases were likely to have been between October and November 2019\nThe scientific consensus is that the virus is most likely of a zoonotic origin from bats or another closely related mammal\nWhile other explanations such as speculations that SARS-CoV-2 was accidentally released from a laboratory have been proposed as of 2021 these were not supported by evidence\n Cases Official case counts refer to the number of people who have been tested for COVID-19 and whose test has been confirmed positive according to official protocols whether or not they experienced symptomatic disease", "evidence": "The first cases may have been between October and November.\nThe virus is most likely a zoonotic origin from bats or another closely related mammal according to the scientific consensus.\nThere are other explanations that were not supported by the evidence as of 2021.\nThe number of people who have been tested for COVID-19 and whose test has been confirmed positive is referred to as an official case count.", "einfo": {"ss": [0.83, 0.67, 0.44, 0.57], "cs": [1.0], "pv": [["first cases"], [], [], ["confirmed positive according"]], "uv": [[], ["origin from bats", "bats or another"], ["supported by evidence", "accidentally released"], ["case counts refer", "experienced symptomatic disease"]]}, "hf": 0}
{"context": "While other explanations such as speculations that SARS-CoV-2 was accidentally released from a laboratory have been proposed as of 2021 these were not supported by evidence\n Cases Official case counts refer to the number of people who have been tested for COVID-19 and whose test has been confirmed positive according to official protocols whether or not they experienced symptomatic disease\nDue to the effect of sampling bias studies which obtain a more accurate number by extrapolating from a random sample have consistently found that total infections considerably exceed the reported case counts", "evidence": "There are other explanations that were not supported by the evidence as of 2021.\nThe number of people who have been tested for COVID-19 and whose test has been confirmed positive is referred to as an official case count.\nDue to the effect of sampling bias studies which get a more accurate number by extrapolating from a random sample have found that infections considerably exceed the reported case counts.", "einfo": {"ss": [0.44, 0.57, 1.0], "cs": [1.0], "pv": [[], ["confirmed positive according"], []], "uv": [["supported by evidence", "accidentally released"], ["case counts refer", "experienced symptomatic disease"], []]}, "hf": 0}
{"context": "While other explanations such as speculations that SARS-CoV-2 was accidentally released from a laboratory have been proposed as of 2021 these were not supported by evidence\n Cases Official case counts refer to the number of people who have been tested for COVID-19 and whose test has been confirmed positive according to official protocols whether or not they experienced symptomatic disease\nDue to the effect of sampling bias studies which obtain a more accurate number by extrapolating from a random sample have consistently found that total infections considerably exceed the reported case counts\nMany countries early on had official policies to not test those with only mild symptoms\nThe strongest risk factors for severe illness are obesity complications of diabetes anxiety disorders and the total number of conditions", "evidence": "There are other explanations that were not supported by the evidence as of 2021.\nThe number of people who have been tested for COVID-19 and whose test has been confirmed positive is referred to as an official case count.\nDue to the effect of sampling bias studies which get a more accurate number by extrapolating from a random sample have found that infections considerably exceed the reported case counts.\nEarly on, many countries did not test for mild symptoms.\nThere are a number of risk factors for severe illness.", "einfo": {"ss": [0.44, 0.57, 1.0, 0.56, 0.79], "cs": [1.0], "pv": [[], ["confirmed positive according"], [], ["Many countries early"], ["strongest risk factors", "number of conditions"]], "uv": [["supported by evidence", "accidentally released"], ["case counts refer", "experienced symptomatic disease"], [], ["official policies"], []]}, "hf": 0}
{"context": "Cases Official case counts refer to the number of people who have been tested for COVID-19 and whose test has been confirmed positive according to official protocols whether or not they experienced symptomatic disease\nDue to the effect of sampling bias studies which obtain a more accurate number by extrapolating from a random sample have consistently found that total infections considerably exceed the reported case counts\nMany countries early on had official policies to not test those with only mild symptoms\nThe strongest risk factors for severe illness are obesity complications of diabetes anxiety disorders and the total number of conditions", "evidence": "The number of people who have been tested for COVID-19 and whose test has been confirmed positive is referred to as an official case count.\nDue to the effect of sampling bias studies which get a more accurate number by extrapolating from a random sample have found that infections considerably exceed the reported case counts.\nEarly on, many countries did not test for mild symptoms.\nThere are a number of risk factors for severe illness.", "einfo": {"ss": [0.57, 1.0, 0.56, 0.79], "cs": [1.0], "pv": [["confirmed positive according"], [], ["Many countries early"], ["strongest risk factors", "number of conditions"]], "uv": [["case counts refer", "experienced symptomatic disease"], [], ["official policies"], []]}, "hf": 0}
{"context": "Many countries early on had official policies to not test those with only mild symptoms\nThe strongest risk factors for severe illness are obesity complications of diabetes anxiety disorders and the total number of conditions\nDuring the start of the COVID-19 pandemic it was not clear whether young people were less likely to be infected or less likely to develop symptoms and be tested\nA retrospective cohort study in China found that children and adults were just as likely to be infected", "evidence": "Early on, many countries did not test for mild symptoms.\nThere are a number of risk factors for severe illness.\nIt wasn't clear if young people were less likely to develop symptoms and be tested during the start of the COVID-19 Pandemic.\nA study in China found that children and adults were equally likely to be exposed to the disease.", "einfo": {"ss": [0.56, 0.79, 0.86, 0.67], "cs": [1.0], "pv": [["Many countries early"], ["strongest risk factors", "number of conditions"], ["whether young people", "clear whether young"], []], "uv": [["official policies"], [], [], ["retrospective cohort study", "infected"]]}, "hf": 0}
{"context": "The strongest risk factors for severe illness are obesity complications of diabetes anxiety disorders and the total number of conditions\nDuring the start of the COVID-19 pandemic it was not clear whether young people were less likely to be infected or less likely to develop symptoms and be tested", "evidence": "There are a number of risk factors for severe illness.\nIt wasn't clear if young people were less likely to develop symptoms and be tested during the start of the COVID-19 Pandemic.", "einfo": {"ss": [0.79, 0.86], "cs": [1.0], "pv": [["strongest risk factors", "number of conditions"], ["whether young people", "clear whether young"]], "uv": [[], []]}, "hf": 0}
{"context": "During the start of the COVID-19 pandemic it was not clear whether young people were less likely to be infected or less likely to develop symptoms and be tested\nA retrospective cohort study in China found that children and adults were just as likely to be infected\nAmong more thorough studies preliminary results from 9 April 2020 found that in Gangelt the centre of a major infection cluster in Germany 15 per cent of a population sample tested positive for antibodies\nScreening for COVID-19 in pregnant women in New York City and blood donors in the Netherlands found rates of positive antibody tests that indicated more infections than reported", "evidence": "It wasn't clear if young people were less likely to develop symptoms and be tested during the start of the COVID-19 Pandemic.\nA study in China found that children and adults were equally likely to be exposed to the disease.\nIn the centre of a major infection cluster in Germany, 15 percent of a population sample tested positive for antibodies, according to preliminary results from 9 April 2020.\nTesting for COVID-19 in pregnant women in New York City and blood donors in the Netherlands found more positive tests than reported.", "einfo": {"ss": [0.86, 0.67, 0.87, 0.83], "cs": [1.0], "pv": [["whether young people", "clear whether young"], [], [], ["Netherlands found rates", "infections than reported"]], "uv": [[], ["retrospective cohort study", "infected"], ["thorough studies preliminary"], []]}, "hf": 0}
{"context": "During the start of the COVID-19 pandemic it was not clear whether young people were less likely to be infected or less likely to develop symptoms and be tested\nA retrospective cohort study in China found that children and adults were just as likely to be infected\nAmong more thorough studies preliminary results from 9 April 2020 found that in Gangelt the centre of a major infection cluster in Germany 15 per cent of a population sample tested positive for antibodies", "evidence": "It wasn't clear if young people were less likely to develop symptoms and be tested during the start of the COVID-19 Pandemic.\nA study in China found that children and adults were equally likely to be exposed to the disease.\nIn the centre of a major infection cluster in Germany, 15 percent of a population sample tested positive for antibodies, according to preliminary results from 9 April 2020.", "einfo": {"ss": [0.86, 0.67, 0.87], "cs": [1.0], "pv": [["whether young people", "clear whether young"], [], []], "uv": [[], ["retrospective cohort study", "infected"], ["thorough studies preliminary"]]}, "hf": 0}
{"context": "Among more thorough studies preliminary results from 9 April 2020 found that in Gangelt the centre of a major infection cluster in Germany 15 per cent of a population sample tested positive for antibodies\nScreening for COVID-19 in pregnant women in New York City and blood donors in the Netherlands found rates of positive antibody tests that indicated more infections than reported\nSeroprevalence-based estimates are conservative as some studies show that persons with mild symptoms do not have detectable antibodies\nInitial estimates of the basic reproduction number R0 for COVID-19 in January 2020 were between 14 and 25 but a subsequent analysis claimed that it may be about 57 with a 95 per cent confidence interval of 38 to 89", "evidence": "In the centre of a major infection cluster in Germany, 15 percent of a population sample tested positive for antibodies, according to preliminary results from 9 April 2020.\nTesting for COVID-19 in pregnant women in New York City and blood donors in the Netherlands found more positive tests than reported.\nSeroprevalence-based estimates are conservative, as some studies show that people with mild symptoms don't have anything to worry about.\nInitial estimates of the basic reproduction number R0 for COVID-19 in January 2020 were between 14 and 25 but a later analysis claimed that it may be 57 with a 95 percent confidence interval.", "einfo": {"ss": [0.87, 0.83, 0.71, 0.75], "cs": [1.0], "pv": [[], ["Netherlands found rates", "infections than reported"], ["show that persons", "persons with mild"], ["cent confidence interval", "subsequent analysis claimed"]], "uv": [["thorough studies preliminary"], [], ["detectable antibodies"], []]}, "hf": 0}
{"context": "Among more thorough studies preliminary results from 9 April 2020 found that in Gangelt the centre of a major infection cluster in Germany 15 per cent of a population sample tested positive for antibodies\nScreening for COVID-19 in pregnant women in New York City and blood donors in the Netherlands found rates of positive antibody tests that indicated more infections than reported\nSeroprevalence-based estimates are conservative as some studies show that persons with mild symptoms do not have detectable antibodies\nInitial estimates of the basic reproduction number R0 for COVID-19 in January 2020 were between 14 and 25 but a subsequent analysis claimed that it may be about 57 with a 95 per cent confidence interval of 38 to 89\nIn December 2021 the number of cases continued to climb due to several factors including new COVID-19 variants", "evidence": "In the centre of a major infection cluster in Germany, 15 percent of a population sample tested positive for antibodies, according to preliminary results from 9 April 2020.\nTesting for COVID-19 in pregnant women in New York City and blood donors in the Netherlands found more positive tests than reported.\nSeroprevalence-based estimates are conservative, as some studies show that people with mild symptoms don't have anything to worry about.\nInitial estimates of the basic reproduction number R0 for COVID-19 in January 2020 were between 14 and 25 but a later analysis claimed that it may be 57 with a 95 percent confidence interval.\nThere were several factors that contributed to the increase in the number of cases in December of 2011.", "einfo": {"ss": [0.87, 0.83, 0.71, 0.75, 0.53], "cs": [1.0], "pv": [[], ["Netherlands found rates", "infections than reported"], ["show that persons", "persons with mild"], ["cent confidence interval", "subsequent analysis claimed"], ["several factors including"]], "uv": [["thorough studies preliminary"], [], ["detectable antibodies"], [], ["cases continued", "factors including new"]]}, "hf": 0}
{"context": "Screening for COVID-19 in pregnant women in New York City and blood donors in the Netherlands found rates of positive antibody tests that indicated more infections than reported\nSeroprevalence-based estimates are conservative as some studies show that persons with mild symptoms do not have detectable antibodies\nInitial estimates of the basic reproduction number R0 for COVID-19 in January 2020 were between 14 and 25 but a subsequent analysis claimed that it may be about 57 with a 95 per cent confidence interval of 38 to 89\nIn December 2021 the number of cases continued to climb due to several factors including new COVID-19 variants\nAs of that 28 December 282790822 individuals worldwide had been confirmed as infected", "evidence": "Testing for COVID-19 in pregnant women in New York City and blood donors in the Netherlands found more positive tests than reported.\nSeroprevalence-based estimates are conservative, as some studies show that people with mild symptoms don't have anything to worry about.\nInitial estimates of the basic reproduction number R0 for COVID-19 in January 2020 were between 14 and 25 but a later analysis claimed that it may be 57 with a 95 percent confidence interval.\nThere were several factors that contributed to the increase in the number of cases in December of 2011.\nAs of December 28, the number of people confirmed as having the disease had increased.", "einfo": {"ss": [0.83, 0.71, 0.75, 0.53, 0.08], "cs": [1.0], "pv": [["Netherlands found rates", "infections than reported"], ["show that persons", "persons with mild"], ["cent confidence interval", "subsequent analysis claimed"], ["several factors including"], []], "uv": [[], ["detectable antibodies"], [], ["cases continued", "factors including new"], ["confirmed as infected", "individuals worldwide", "December"]]}, "hf": 0}
{"context": "As of that 28 December 282790822 individuals worldwide had been confirmed as infected\nAs of 14 April 2022 over 500 million cases were confirmed globally\nMost cases are unconfirmed with the Institute for Health Metrics and Evaluation estimating the true number of cases as of early 2022 to be in the billions", "evidence": "As of December 28, the number of people confirmed as having the disease had increased.\nOver 500 million cases were confirmed by the end of April.\nThe true number of cases is estimated by the Institute for Health Metrics and Evaluation at billions.", "einfo": {"ss": [0.08, 0.78, 0.82], "cs": [1.0], "pv": [[], [], ["cases are unconfirmed"]], "uv": [["confirmed as infected", "individuals worldwide", "December"], ["April"], ["Evaluation estimating"]]}, "hf": 0}
{"context": "As of 14 April 2022 over 500 million cases were confirmed globally\nMost cases are unconfirmed with the Institute for Health Metrics and Evaluation estimating the true number of cases as of early 2022 to be in the billions\n Test positivity rate One measure that public health officials and policymakers have used to monitor the pandemic and guide decision-making is the test positivity rate percent positive", "evidence": "Over 500 million cases were confirmed by the end of April.\nThe true number of cases is estimated by the Institute for Health Metrics and Evaluation at billions.\nThe test positivity rate is a measure used by public health officials and policymakers to monitor and guide decision-making.", "einfo": {"ss": [0.78, 0.82, 0.56], "cs": [1.0], "pv": [[], ["cases are unconfirmed"], []], "uv": [["April"], ["Evaluation estimating"], ["rate One measure", "positivity rate percent"]]}, "hf": 0}
{"context": "As of 14 April 2022 over 500 million cases were confirmed globally\nMost cases are unconfirmed with the Institute for Health Metrics and Evaluation estimating the true number of cases as of early 2022 to be in the billions\n Test positivity rate One measure that public health officials and policymakers have used to monitor the pandemic and guide decision-making is the test positivity rate percent positive\nAccording to Johns Hopkins in 2020 one benchmark for a too high per cent positive is 5% which was used by the WHO in the past", "evidence": "Over 500 million cases were confirmed by the end of April.\nThe true number of cases is estimated by the Institute for Health Metrics and Evaluation at billions.\nThe test positivity rate is a measure used by public health officials and policymakers to monitor and guide decision-making.\nThe WHO used to use a benchmark of 5% for too high a per cent positive.", "einfo": {"ss": [0.78, 0.82, 0.56, 0.5], "cs": [1.0], "pv": [[], ["cases are unconfirmed"], [], ["high per cent"]], "uv": [["April"], ["Evaluation estimating"], ["rate One measure", "positivity rate percent"], ["one benchmark", "According to Johns"]]}, "hf": 0}
{"context": "Test positivity rate One measure that public health officials and policymakers have used to monitor the pandemic and guide decision-making is the test positivity rate percent positive\nAccording to Johns Hopkins in 2020 one benchmark for a too high per cent positive is 5% which was used by the WHO in the past\n Deaths As of 10 March 2023 more than 688 million deaths had been attributed to COVID-19", "evidence": "The test positivity rate is a measure used by public health officials and policymakers to monitor and guide decision-making.\nThe WHO used to use a benchmark of 5% for too high a per cent positive.\nMore than 700 million deaths were attributed to COVID-19.", "einfo": {"ss": [0.56, 0.5, 0.67], "cs": [1.0], "pv": [[], ["high per cent"], []], "uv": [["rate One measure", "positivity rate percent"], ["one benchmark", "According to Johns"], ["attributed"]]}, "hf": 0}
{"context": "The first confirmed death was in Wuhan on 9 January 2020\nThese numbers vary by region and over time influenced by testing volume healthcare system quality treatment options government response time since the initial outbreak and population characteristics such as age sex and overall health\nMultiple measures are used to quantify mortality\nOfficial death counts typically include people who died after testing positive", "evidence": "On January 9, 2020, the first death was confirmed.\nThe number varies by region and over time is influenced by testing volume healthcare system quality treatment options and government response time since the initial outbreak.\nMortality can be quantified using multiple measures.\nPeople who died after testing positive are included in official death counts.", "einfo": {"ss": [0.56, 0.7, 0.58, 0.55], "cs": [1.0], "pv": [["first confirmed death"], [], ["Multiple measures", "used to quantify"], []], "uv": [["Wuhan"], ["treatment options government", "options government response", "overall health"], [], ["typically include people", "counts typically include"]]}, "hf": 0}
{"context": "Multiple measures are used to quantify mortality\nOfficial death counts typically include people who died after testing positive\nSuch counts exclude deaths without a test", "evidence": "Mortality can be quantified using multiple measures.\nPeople who died after testing positive are included in official death counts.\nDeaths without a test are excluded from such counts.", "einfo": {"ss": [0.58, 0.55, 0.62], "cs": [1.0], "pv": [["Multiple measures", "used to quantify"], [], ["exclude deaths without"]], "uv": [[], ["typically include people", "counts typically include"], ["counts exclude deaths"]]}, "hf": 0}
{"context": "Such counts exclude deaths without a test\nConversely deaths of people who died from underlying conditions following a positive test may be included\nCountries such as Belgium include deaths from suspected cases including those without a test thereby increasing counts\nOfficial death counts have been claimed to underreport the actual death toll because excess mortality the number of deaths in a period compared to a long-term average data show an increase in deaths that is not explained by COVID-19 deaths alone", "evidence": "Deaths without a test are excluded from such counts.\nThe deaths of people who died from underlying conditions may be included in the positive test deaths.\nDeaths from suspected cases are included in countries such as Belgium.\nThe excess deaths in a period compared to the long-term average data show an increase in deaths that are not explained by COVID-19 deaths alone.", "einfo": {"ss": [0.62, 0.8, 0.4, 0.6], "cs": [1.0], "pv": [["exclude deaths without"], ["underlying conditions following", "positive test may"], ["suspected cases including"], []], "uv": [["counts exclude deaths"], [], ["Belgium include deaths", "thereby increasing counts", "test thereby increasing"], ["excess mortality", "Official death counts", "claimed to underreport"]]}, "hf": 0}
{"context": "Such counts exclude deaths without a test\nConversely deaths of people who died from underlying conditions following a positive test may be included\nCountries such as Belgium include deaths from suspected cases including those without a test thereby increasing counts", "evidence": "Deaths without a test are excluded from such counts.\nThe deaths of people who died from underlying conditions may be included in the positive test deaths.\nDeaths from suspected cases are included in countries such as Belgium.", "einfo": {"ss": [0.62, 0.8, 0.4], "cs": [1.0], "pv": [["exclude deaths without"], ["underlying conditions following", "positive test may"], ["suspected cases including"]], "uv": [["counts exclude deaths"], [], ["Belgium include deaths", "thereby increasing counts", "test thereby increasing"]]}, "hf": 0}
{"context": "Countries such as Belgium include deaths from suspected cases including those without a test thereby increasing counts\nOfficial death counts have been claimed to underreport the actual death toll because excess mortality the number of deaths in a period compared to a long-term average data show an increase in deaths that is not explained by COVID-19 deaths alone\nUsing such data estimates of the true number of deaths from COVID-19 worldwide have included a range from 182 to 335 million \u2248274 million by 18 November 2023 by The Economist as well as over 185 million by 1 April 2023 by the Institute for Health Metrics and Evaluation and \u2248182 million earlier deaths between 1 January 2020 and 31 December 2021 by a comprehensive international study", "evidence": "Deaths from suspected cases are included in countries such as Belgium.\nThe excess deaths in a period compared to the long-term average data show an increase in deaths that are not explained by COVID-19 deaths alone.\nEstimates of the true number of deaths from COVID-19 worldwide have been used by The Economist and the Institute for Health Metrics and Evaluation.", "einfo": {"ss": [0.4, 0.6, 0.59], "cs": [1.0], "pv": [["suspected cases including"], [], []], "uv": [["Belgium include deaths", "thereby increasing counts", "test thereby increasing"], ["excess mortality", "Official death counts", "claimed to underreport"], ["Economist as well", "million earlier deaths", "comprehensive international study"]]}, "hf": 0}
{"context": "Official death counts have been claimed to underreport the actual death toll because excess mortality the number of deaths in a period compared to a long-term average data show an increase in deaths that is not explained by COVID-19 deaths alone\nUsing such data estimates of the true number of deaths from COVID-19 worldwide have included a range from 182 to 335 million \u2248274 million by 18 November 2023 by The Economist as well as over 185 million by 1 April 2023 by the Institute for Health Metrics and Evaluation and \u2248182 million earlier deaths between 1 January 2020 and 31 December 2021 by a comprehensive international study\nSuch deaths include deaths due to healthcare capacity constraints and priorities as well as reluctance to seek care to avoid possible infection", "evidence": "The excess deaths in a period compared to the long-term average data show an increase in deaths that are not explained by COVID-19 deaths alone.\nEstimates of the true number of deaths from COVID-19 worldwide have been used by The Economist and the Institute for Health Metrics and Evaluation.\nDeaths due to healthcare capacity constraints and priorities as well as reluctance to seek care to avoid possible infections are included in such deaths.", "einfo": {"ss": [0.6, 0.59, 1.0], "cs": [1.0], "pv": [[], [], []], "uv": [["excess mortality", "Official death counts", "claimed to underreport"], ["Economist as well", "million earlier deaths", "comprehensive international study"], []]}, "hf": 0}
{"context": "Official death counts have been claimed to underreport the actual death toll because excess mortality the number of deaths in a period compared to a long-term average data show an increase in deaths that is not explained by COVID-19 deaths alone\nUsing such data estimates of the true number of deaths from COVID-19 worldwide have included a range from 182 to 335 million \u2248274 million by 18 November 2023 by The Economist as well as over 185 million by 1 April 2023 by the Institute for Health Metrics and Evaluation and \u2248182 million earlier deaths between 1 January 2020 and 31 December 2021 by a comprehensive international study\nSuch deaths include deaths due to healthcare capacity constraints and priorities as well as reluctance to seek care to avoid possible infection\nFurther research may help distinguish the proportions directly caused by COVID-19 from those caused by indirect consequences of the pandemic\nIn May 2022 the WHO estimated the number of excess deaths by the end of 2021 to be 149 million compared to 54 million reported COVID-19 deaths with the majority of the unreported 95 million deaths believed to be direct deaths due the virus rather than indirect deaths", "evidence": "The excess deaths in a period compared to the long-term average data show an increase in deaths that are not explained by COVID-19 deaths alone.\nEstimates of the true number of deaths from COVID-19 worldwide have been used by The Economist and the Institute for Health Metrics and Evaluation.\nDeaths due to healthcare capacity constraints and priorities as well as reluctance to seek care to avoid possible infections are included in such deaths.\nThe proportions caused by COVID-19 may be different from those caused by indirect consequences.\nThe WHO estimated the number of excess deaths to be 149 million by the end of 2021.", "einfo": {"ss": [0.6, 0.59, 1.0, 0.47, 0.55], "cs": [1.0], "pv": [[], [], [], ["proportions directly caused"], ["million reported"]], "uv": [["excess mortality", "Official death counts", "claimed to underreport"], ["Economist as well", "million earlier deaths", "comprehensive international study"], [], ["may help distinguish", "distinguish the proportions"], ["million deaths believed", "rather than indirect"]]}, "hf": 0}
{"context": "Using such data estimates of the true number of deaths from COVID-19 worldwide have included a range from 182 to 335 million \u2248274 million by 18 November 2023 by The Economist as well as over 185 million by 1 April 2023 by the Institute for Health Metrics and Evaluation and \u2248182 million earlier deaths between 1 January 2020 and 31 December 2021 by a comprehensive international study\nSuch deaths include deaths due to healthcare capacity constraints and priorities as well as reluctance to seek care to avoid possible infection\nFurther research may help distinguish the proportions directly caused by COVID-19 from those caused by indirect consequences of the pandemic\nIn May 2022 the WHO estimated the number of excess deaths by the end of 2021 to be 149 million compared to 54 million reported COVID-19 deaths with the majority of the unreported 95 million deaths believed to be direct deaths due the virus rather than indirect deaths", "evidence": "Estimates of the true number of deaths from COVID-19 worldwide have been used by The Economist and the Institute for Health Metrics and Evaluation.\nDeaths due to healthcare capacity constraints and priorities as well as reluctance to seek care to avoid possible infections are included in such deaths.\nThe proportions caused by COVID-19 may be different from those caused by indirect consequences.\nThe WHO estimated the number of excess deaths to be 149 million by the end of 2021.", "einfo": {"ss": [0.59, 1.0, 0.47, 0.55], "cs": [1.0], "pv": [[], [], ["proportions directly caused"], ["million reported"]], "uv": [["Economist as well", "million earlier deaths", "comprehensive international study"], [], ["may help distinguish", "distinguish the proportions"], ["million deaths believed", "rather than indirect"]]}, "hf": 0}
{"context": "Further research may help distinguish the proportions directly caused by COVID-19 from those caused by indirect consequences of the pandemic\nIn May 2022 the WHO estimated the number of excess deaths by the end of 2021 to be 149 million compared to 54 million reported COVID-19 deaths with the majority of the unreported 95 million deaths believed to be direct deaths due the virus rather than indirect deaths\nSome deaths were because people with other conditions could not access medical services\nA December 2022 WHO study estimated excess deaths from the pandemic during 2020 and 2021 again concluding \u2248148 million excess early deaths occurred reaffirming and detailing their prior calculations from May as well as updating them addressing criticisms", "evidence": "The proportions caused by COVID-19 may be different from those caused by indirect consequences.\nThe WHO estimated the number of excess deaths to be 149 million by the end of 2021.\nSome deaths were due to people not being able to get medical services.\nA December 2022 WHO study estimated excess deaths from the Pandemic during 2020 and 2021, again concluding 148 million excess early deaths occurred, as well as detailing their prior calculations from May.", "einfo": {"ss": [0.47, 0.55, 0.29, 1.0], "cs": [1.0], "pv": [["proportions directly caused"], ["million reported"], ["access medical services"], []], "uv": [["may help distinguish", "distinguish the proportions"], ["million deaths believed", "rather than indirect"], ["deaths", "people", "conditions could"], []]}, "hf": 0}
{"context": "Further research may help distinguish the proportions directly caused by COVID-19 from those caused by indirect consequences of the pandemic\nIn May 2022 the WHO estimated the number of excess deaths by the end of 2021 to be 149 million compared to 54 million reported COVID-19 deaths with the majority of the unreported 95 million deaths believed to be direct deaths due the virus rather than indirect deaths\nSome deaths were because people with other conditions could not access medical services", "evidence": "The proportions caused by COVID-19 may be different from those caused by indirect consequences.\nThe WHO estimated the number of excess deaths to be 149 million by the end of 2021.\nSome deaths were due to people not being able to get medical services.", "einfo": {"ss": [0.47, 0.55, 0.29], "cs": [1.0], "pv": [["proportions directly caused"], ["million reported"], ["access medical services"]], "uv": [["may help distinguish", "distinguish the proportions"], ["million deaths believed", "rather than indirect"], ["deaths", "people", "conditions could"]]}, "hf": 0}
{"context": "Some deaths were because people with other conditions could not access medical services\nA December 2022 WHO study estimated excess deaths from the pandemic during 2020 and 2021 again concluding \u2248148 million excess early deaths occurred reaffirming and detailing their prior calculations from May as well as updating them addressing criticisms\nThese numbers do not include measures like years of potential life lost and may make the pandemic 2021s leading cause of death\nThe time between symptom onset and death ranges from 6 to 41 days typically about 14 days", "evidence": "Some deaths were due to people not being able to get medical services.\nA December 2022 WHO study estimated excess deaths from the Pandemic during 2020 and 2021, again concluding 148 million excess early deaths occurred, as well as detailing their prior calculations from May.\nThe numbers don't include measures like years of potential life lost, which could make the swine flu the leading cause of death.\nTypically, the time between symptom onset and death is 14 days.", "einfo": {"ss": [0.29, 1.0, 1.0, 0.7], "cs": [1.0], "pv": [["access medical services"], [], [], ["days typically"]], "uv": [["deaths", "people", "conditions could"], [], [], ["death ranges"]]}, "hf": 0}
{"context": "Some deaths were because people with other conditions could not access medical services\nA December 2022 WHO study estimated excess deaths from the pandemic during 2020 and 2021 again concluding \u2248148 million excess early deaths occurred reaffirming and detailing their prior calculations from May as well as updating them addressing criticisms\nThese numbers do not include measures like years of potential life lost and may make the pandemic 2021s leading cause of death", "evidence": "Some deaths were due to people not being able to get medical services.\nA December 2022 WHO study estimated excess deaths from the Pandemic during 2020 and 2021, again concluding 148 million excess early deaths occurred, as well as detailing their prior calculations from May.\nThe numbers don't include measures like years of potential life lost, which could make the swine flu the leading cause of death.", "einfo": {"ss": [0.29, 1.0, 1.0], "cs": [1.0], "pv": [["access medical services"], [], []], "uv": [["deaths", "people", "conditions could"], [], []]}, "hf": 0}
{"context": "Mortality rates increase as a function of age\nPeople at the greatest mortality risk are the elderly and those with underlying conditions\n Infection fatality ratio IFR The infection fatality ratio IFR is the cumulative number of deaths attributed to the disease divided by the cumulative number of infected individuals including asymptomatic and undiagnosed infections and excluding vaccinated infected individuals\nIt is expressed in percentage points", "evidence": "Mortality rates go up as you get older.\nThe elderly and people with underlying conditions are at the greatest mortality risk.\nThe infections fatality ratio is the cumulative number of deaths attributed to the disease divided by the number of infections.\nPercentage points are where it is expressed.", "einfo": {"ss": [0.33, 0.56, 0.4, 1.0], "cs": [1.0], "pv": [["Mortality rates increase"], [], [], []], "uv": [["function of age"], ["People", "elderly"], ["individuals including asymptomatic", "vaccinated infected individuals", "infected individuals including"], []]}, "hf": 0}
{"context": "Other studies refer to this metric as the infection fatality risk\nIn November 2020 a review article in Nature reported estimates of population-weighted IFRs for various countries excluding deaths in elderly care facilities and found a median range of 024% to 149%\nIFRs rise as a function of age from 0002% at age 10 and 001% at age 25 to 04% at age 55 14% at age 65 46% at age 75 and 15% at age 85", "evidence": "The metric is referred to as the death risk by other studies.\nIn November 2020, a review article in Nature reported estimates of population-weighted IFRs for various countries, with a median range of 149%.\nAt age 10 and 01%, at age 25 to 04%), at age 55 to 46%, and at age 75 to 15%, IFRs increase as a function of age.", "einfo": {"ss": [0.36, 0.94, 0.33], "cs": [1.0], "pv": [["studies refer"], ["various countries excluding"], []], "uv": [["metric", "infection fatality risk"], [], ["IFRs rise", "function of age"]]}, "hf": 0}
{"context": "IFRs rise as a function of age from 0002% at age 10 and 001% at age 25 to 04% at age 55 14% at age 65 46% at age 75 and 15% at age 85\nThese rates vary by a factor of \u224810000 across the age groups\nFor comparison the IFR for middle-aged adults is two orders of magnitude higher than the annualised risk of a fatal automobile accident and much higher than the risk of dying from seasonal influenza\nIn December 2020 a systematic review and meta-analysis estimated that population-weighted IFR was 05% to 1% in some countries France Netherlands New Zealand and Portugal 1% to 2% in other countries Australia England Lithuania and Spain and about 25% in Italy", "evidence": "At age 10 and 01%, at age 25 to 04%), at age 55 to 46%, and at age 75 to 15%, IFRs increase as a function of age.\nThe rates vary by a factor of 10000 across the age groups, as shown by the 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846\nThe annualised risk of a fatal automobile accident is two orders of magnitude higher than the IFR for middle-aged adults.\nIn December 2020, a systematic review and meta-analysis estimated the population-weighted IFR to be between 1% and 2% in some countries.", "einfo": {"ss": [0.33, 1.0, 0.75, 0.03], "cs": [1.0], "pv": [[], [], ["adults is two"], []], "uv": [["IFRs rise", "function of age"], [], ["orders of magnitude"], ["Zealand and Portugal", "countries France Netherlands", "Australia England Lithuania", "countries Australia England", "Netherlands New Zealand", "France Netherlands New"]]}, "hf": 0}
{"context": "These rates vary by a factor of \u224810000 across the age groups\nFor comparison the IFR for middle-aged adults is two orders of magnitude higher than the annualised risk of a fatal automobile accident and much higher than the risk of dying from seasonal influenza\nIn December 2020 a systematic review and meta-analysis estimated that population-weighted IFR was 05% to 1% in some countries France Netherlands New Zealand and Portugal 1% to 2% in other countries Australia England Lithuania and Spain and about 25% in Italy", "evidence": "The rates vary by a factor of 10000 across the age groups, as shown by the 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846 888-666-1846\nThe annualised risk of a fatal automobile accident is two orders of magnitude higher than the IFR for middle-aged adults.\nIn December 2020, a systematic review and meta-analysis estimated the population-weighted IFR to be between 1% and 2% in some countries.", "einfo": {"ss": [1.0, 0.75, 0.03], "cs": [1.0], "pv": [[], ["adults is two"], []], "uv": [[], ["orders of magnitude"], ["Zealand and Portugal", "countries France Netherlands", "Australia England Lithuania", "countries Australia England", "Netherlands New Zealand", "France Netherlands New"]]}, "hf": 0}
{"context": "In December 2020 a systematic review and meta-analysis estimated that population-weighted IFR was 05% to 1% in some countries France Netherlands New Zealand and Portugal 1% to 2% in other countries Australia England Lithuania and Spain and about 25% in Italy\nThis study reported that most of the differences reflected corresponding differences in the populations age structure and the age-specific pattern of infections\nThere have also been reviews that have compared the fatality rate of this pandemic with prior pandemics such as MERS-CoV", "evidence": "In December 2020, a systematic review and meta-analysis estimated the population-weighted IFR to be between 1% and 2% in some countries.\nThe age-specific pattern of infections and the populations age structure were reflected in most of the differences.\nThe fatality rate of the Pandemic has been compared to previous Pandemics.", "einfo": {"ss": [0.03, 0.8, 0.51], "cs": [1.0], "pv": [[], [], []], "uv": [["Zealand and Portugal", "countries France Netherlands", "Australia England Lithuania", "countries Australia England", "Netherlands New Zealand", "France Netherlands New"], ["reflected corresponding differences"], ["prior pandemics", "compared the fatality"]]}, "hf": 0}
{"context": "This study reported that most of the differences reflected corresponding differences in the populations age structure and the age-specific pattern of infections\nThere have also been reviews that have compared the fatality rate of this pandemic with prior pandemics such as MERS-CoV\nFor comparison the infection mortality rate of seasonal flu in the United States is 01% which is 13 times lower than COVID-19", "evidence": "The age-specific pattern of infections and the populations age structure were reflected in most of the differences.\nThe fatality rate of the Pandemic has been compared to previous Pandemics.\nThe seasonal flu mortality rate in the United States is zero, which is 13 times lower than COVID-19.", "einfo": {"ss": [0.8, 0.51, 0.63], "cs": [1.0], "pv": [[], [], ["seasonal flu", "infection mortality rate"]], "uv": [["reflected corresponding differences"], ["prior pandemics", "compared the fatality"], ["comparison the infection"]]}, "hf": 0}
{"context": "There have also been reviews that have compared the fatality rate of this pandemic with prior pandemics such as MERS-CoV\nFor comparison the infection mortality rate of seasonal flu in the United States is 01% which is 13 times lower than COVID-19\n Case fatality ratio CFR Another metric in assessing death rate is the case fatality ratio CFR which is the ratio of deaths to diagnoses\nThis metric can be misleading because of the delay between symptom onset and death and because testing focuses on symptomatic individuals", "evidence": "The fatality rate of the Pandemic has been compared to previous Pandemics.\nThe seasonal flu mortality rate in the United States is zero, which is 13 times lower than COVID-19.\nThe ratio of deaths to diagnoses is the case fatality ratio CFR.\nThe delay between symptom onset and death can make this metric misleading.", "einfo": {"ss": [0.51, 0.63, 0.73, 0.58], "cs": [1.0], "pv": [[], ["seasonal flu", "infection mortality rate"], [], ["metric"]], "uv": [["prior pandemics", "compared the fatality"], ["comparison the infection"], ["assessing death rate"], ["symptomatic individuals", "focuses on symptomatic"]]}, "hf": 0}
{"context": "For comparison the infection mortality rate of seasonal flu in the United States is 01% which is 13 times lower than COVID-19\n Case fatality ratio CFR Another metric in assessing death rate is the case fatality ratio CFR which is the ratio of deaths to diagnoses\nThis metric can be misleading because of the delay between symptom onset and death and because testing focuses on symptomatic individuals\nBased on Johns Hopkins University statistics the global CFR was 102 percent 6881955 deaths for 676609955 cases as of 10 March 2023", "evidence": "The seasonal flu mortality rate in the United States is zero, which is 13 times lower than COVID-19.\nThe ratio of deaths to diagnoses is the case fatality ratio CFR.\nThe delay between symptom onset and death can make this metric misleading.\nAs of 10 March, the global CFR was over 100 percent with 6881955 deaths.", "einfo": {"ss": [0.63, 0.73, 0.58, 0.75], "cs": [1.0], "pv": [["seasonal flu", "infection mortality rate"], [], ["metric"], []], "uv": [["comparison the infection"], ["assessing death rate"], ["symptomatic individuals", "focuses on symptomatic"], ["Hopkins University statistics"]]}, "hf": 0}
{"context": "For comparison the infection mortality rate of seasonal flu in the United States is 01% which is 13 times lower than COVID-19\n Case fatality ratio CFR Another metric in assessing death rate is the case fatality ratio CFR which is the ratio of deaths to diagnoses\nThis metric can be misleading because of the delay between symptom onset and death and because testing focuses on symptomatic individuals\nBased on Johns Hopkins University statistics the global CFR was 102 percent 6881955 deaths for 676609955 cases as of 10 March 2023\nThe number varies by region and has generally declined over time", "evidence": "The seasonal flu mortality rate in the United States is zero, which is 13 times lower than COVID-19.\nThe ratio of deaths to diagnoses is the case fatality ratio CFR.\nThe delay between symptom onset and death can make this metric misleading.\nAs of 10 March, the global CFR was over 100 percent with 6881955 deaths.\nOver time, the number varies by region.", "einfo": {"ss": [0.63, 0.73, 0.58, 0.75, 0.78], "cs": [1.0], "pv": [["seasonal flu", "infection mortality rate"], [], ["metric"], [], []], "uv": [["comparison the infection"], ["assessing death rate"], ["symptomatic individuals", "focuses on symptomatic"], ["Hopkins University statistics"], ["declined over time"]]}, "hf": 0}
{"context": "Case fatality ratio CFR Another metric in assessing death rate is the case fatality ratio CFR which is the ratio of deaths to diagnoses\nThis metric can be misleading because of the delay between symptom onset and death and because testing focuses on symptomatic individuals\nBased on Johns Hopkins University statistics the global CFR was 102 percent 6881955 deaths for 676609955 cases as of 10 March 2023\nThe number varies by region and has generally declined over time", "evidence": "The ratio of deaths to diagnoses is the case fatality ratio CFR.\nThe delay between symptom onset and death can make this metric misleading.\nAs of 10 March, the global CFR was over 100 percent with 6881955 deaths.\nOver time, the number varies by region.", "einfo": {"ss": [0.73, 0.58, 0.75, 0.78], "cs": [1.0], "pv": [[], ["metric"], [], []], "uv": [["assessing death rate"], ["symptomatic individuals", "focuses on symptomatic"], ["Hopkins University statistics"], ["declined over time"]]}, "hf": 0}
{"context": "Based on Johns Hopkins University statistics the global CFR was 102 percent 6881955 deaths for 676609955 cases as of 10 March 2023\nThe number varies by region and has generally declined over time\n Disease  Variants Several variants have been named by WHO and labelled as a variant of concern VoC or a variant of interest VoI\nMany of these variants have shared the more infectious D614G\nAs of May 2023 the WHO had downgraded all variants of concern to previously circulating as these were no longer detected in new infections", "evidence": "As of 10 March, the global CFR was over 100 percent with 6881955 deaths.\nOver time, the number varies by region.\nVoC or a variant of interest is one of the diseases that have been named by WHO.\nThe more infectious D614G has been shared by many of these variations.\nAs of May 2023, the WHO had no longer detected any of the previously circulating concerns.", "einfo": {"ss": [0.75, 0.78, 0.58, 0.44, 0.89], "cs": [1.0], "pv": [[], [], ["concern VoC"], [], ["previously circulating"]], "uv": [["Hopkins University statistics"], ["declined over time"], ["interest VoI"], ["Many", "variants have shared"], []]}, "hf": 0}
{"context": "Disease  Variants Several variants have been named by WHO and labelled as a variant of concern VoC or a variant of interest VoI\nMany of these variants have shared the more infectious D614G\nAs of May 2023 the WHO had downgraded all variants of concern to previously circulating as these were no longer detected in new infections\nSub-lineages of the Omicron variant BA1 \u2013 BA5 were considered separate VoCs by the WHO until they were downgraded in March 2023 as no longer widely circulating\nAs of 24 September 2024 the variants of interest as specified by the WHO are BA286 and JN1 and the variants under monitoring are JN17 KP2 KP3 KP311 JN118 LB1 and XEC", "evidence": "VoC or a variant of interest is one of the diseases that have been named by WHO.\nThe more infectious D614G has been shared by many of these variations.\nAs of May 2023, the WHO had no longer detected any of the previously circulating concerns.\nThe WHO classified the sub-lineages of the Omicron variant as separate VoCs until they were no longer widely circulating.\nAs of 24 September 2024, the WHO specified the variant of interest as BA286 and JN1, and the variant under monitoring as jn118 LB1 and xec.", "einfo": {"ss": [0.58, 0.44, 0.89, 0.67, 0.8], "cs": [1.0], "pv": [["concern VoC"], [], ["previously circulating"], [], []], "uv": [["interest VoI"], ["Many", "variants have shared"], [], ["considered separate VoCs"], ["interest as specified"]]}, "hf": 0}
{"context": "Sub-lineages of the Omicron variant BA1 \u2013 BA5 were considered separate VoCs by the WHO until they were downgraded in March 2023 as no longer widely circulating\nAs of 24 September 2024 the variants of interest as specified by the WHO are BA286 and JN1 and the variants under monitoring are JN17 KP2 KP3 KP311 JN118 LB1 and XEC\n Signs and symptoms Symptoms of COVID-19 are variable ranging from mild symptoms to severe illness", "evidence": "The WHO classified the sub-lineages of the Omicron variant as separate VoCs until they were no longer widely circulating.\nAs of 24 September 2024, the WHO specified the variant of interest as BA286 and JN1, and the variant under monitoring as jn118 LB1 and xec.\nThere are different signs and symptoms of COVID-19.", "einfo": {"ss": [0.67, 0.8, 0.5], "cs": [1.0], "pv": [[], [], []], "uv": [["considered separate VoCs"], ["interest as specified"], ["symptoms to severe"]]}, "hf": 0}
{"context": "As of 24 September 2024 the variants of interest as specified by the WHO are BA286 and JN1 and the variants under monitoring are JN17 KP2 KP3 KP311 JN118 LB1 and XEC\n Signs and symptoms Symptoms of COVID-19 are variable ranging from mild symptoms to severe illness\nCommon symptoms include headache loss of smell and taste nasal congestion and runny nose cough muscle pain sore throat fever diarrhoea and breathing difficulties\nPeople with the same infection may have different symptoms and their symptoms may change over time", "evidence": "As of 24 September 2024, the WHO specified the variant of interest as BA286 and JN1, and the variant under monitoring as jn118 LB1 and xec.\nThere are different signs and symptoms of COVID-19.\nheadaches, loss of smell, and taste, sore throat, and breathing difficulties are some of the common symptoms.\nThe symptoms of people with the same infections may change over time.", "einfo": {"ss": [0.8, 0.5, 0.37, 0.67], "cs": [1.0], "pv": [[], [], ["Common symptoms include", "sore throat fever"], ["infection may"]], "uv": [["interest as specified"], ["symptoms to severe"], ["symptoms include headache", "taste nasal congestion", "include headache loss", "nose cough muscle"], ["People"]]}, "hf": 0}
{"context": "Common symptoms include headache loss of smell and taste nasal congestion and runny nose cough muscle pain sore throat fever diarrhoea and breathing difficulties\nPeople with the same infection may have different symptoms and their symptoms may change over time", "evidence": "headaches, loss of smell, and taste, sore throat, and breathing difficulties are some of the common symptoms.\nThe symptoms of people with the same infections may change over time.", "einfo": {"ss": [0.37, 0.67], "cs": [1.0], "pv": [["Common symptoms include", "sore throat fever"], ["infection may"]], "uv": [["symptoms include headache", "taste nasal congestion", "include headache loss", "nose cough muscle"], ["People"]]}, "hf": 0}
{"context": "People with the same infection may have different symptoms and their symptoms may change over time\nThree common clusters of symptoms have been identified one respiratory symptom cluster with cough sputum shortness of breath and fever; a musculoskeletal symptom cluster with muscle and joint pain headache and fatigue; a cluster of digestive symptoms with abdominal pain vomiting and diarrhoea", "evidence": "The symptoms of people with the same infections may change over time.\nThere are three common clusters of symptoms, one of which is a respiratory symptom with cough, sputum, and cold.", "einfo": {"ss": [0.67, 0.51], "cs": [1.0], "pv": [["infection may"], ["respiratory symptom cluster", "musculoskeletal symptom cluster"]], "uv": [["People"], ["cough sputum shortness", "identified one respiratory", "one respiratory symptom"]]}, "hf": 0}
{"context": "Three common clusters of symptoms have been identified one respiratory symptom cluster with cough sputum shortness of breath and fever; a musculoskeletal symptom cluster with muscle and joint pain headache and fatigue; a cluster of digestive symptoms with abdominal pain vomiting and diarrhoea\nIn people without prior ear nose and throat disorders loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 88% of cases\n Transmission The disease is mainly transmitted via the respiratory route when people inhale droplets and small airborne particles that form an aerosol that infected people exhale as they breathe talk cough sneeze or sing\nInfected people are more likely to transmit COVID-19 when they are physically close to other non-infected individuals", "evidence": "There are three common clusters of symptoms, one of which is a respiratory symptom with cough, sputum, and cold.\nIn people without prior ear nose and throat disorders loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 86 percent of cases.\nThe disease is mostly transmitted through the respiratory route when people breathe in droplets and small airborne particles that form an aerosol.\nWhen people are close to each other, they are more likely to transmit COVID-19.", "einfo": {"ss": [0.51, 0.8, 0.27, 0.62], "cs": [1.0], "pv": [["respiratory symptom cluster", "musculoskeletal symptom cluster"], [], ["disease is mainly"], []], "uv": [["cough sputum shortness", "identified one respiratory", "one respiratory symptom"], ["nose and throat"], ["mainly transmitted via", "people inhale droplets", "breathe talk cough", "infected people exhale", "Transmission The disease", "talk cough sneeze", "sneeze or sing"], ["physically close"]]}, "hf": 0}
{"context": "In people without prior ear nose and throat disorders loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 88% of cases\n Transmission The disease is mainly transmitted via the respiratory route when people inhale droplets and small airborne particles that form an aerosol that infected people exhale as they breathe talk cough sneeze or sing\nInfected people are more likely to transmit COVID-19 when they are physically close to other non-infected individuals\nHowever infection can occur over longer distances particularly indoors", "evidence": "In people without prior ear nose and throat disorders loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 86 percent of cases.\nThe disease is mostly transmitted through the respiratory route when people breathe in droplets and small airborne particles that form an aerosol.\nWhen people are close to each other, they are more likely to transmit COVID-19.\nInfections can occur indoors.", "einfo": {"ss": [0.8, 0.27, 0.62, 0.62], "cs": [1.0], "pv": [[], ["disease is mainly"], [], []], "uv": [["nose and throat"], ["mainly transmitted via", "people inhale droplets", "breathe talk cough", "infected people exhale", "Transmission The disease", "talk cough sneeze", "sneeze or sing"], ["physically close"], ["distances particularly indoors"]]}, "hf": 0}
{"context": "Transmission The disease is mainly transmitted via the respiratory route when people inhale droplets and small airborne particles that form an aerosol that infected people exhale as they breathe talk cough sneeze or sing\nInfected people are more likely to transmit COVID-19 when they are physically close to other non-infected individuals\nHowever infection can occur over longer distances particularly indoors\n Cause SARS\u2011CoV\u20112 belongs to the broad family of viruses known as coronaviruses", "evidence": "The disease is mostly transmitted through the respiratory route when people breathe in droplets and small airborne particles that form an aerosol.\nWhen people are close to each other, they are more likely to transmit COVID-19.\nInfections can occur indoors.\ncoronaviruses are a broad family of Viruses.", "einfo": {"ss": [0.27, 0.62, 0.62, 0.78], "cs": [1.0], "pv": [["disease is mainly"], [], [], []], "uv": [["mainly transmitted via", "people inhale droplets", "breathe talk cough", "infected people exhale", "Transmission The disease", "talk cough sneeze", "sneeze or sing"], ["physically close"], ["distances particularly indoors"], ["known as coronaviruses"]]}, "hf": 0}
{"context": "However infection can occur over longer distances particularly indoors\n Cause SARS\u2011CoV\u20112 belongs to the broad family of viruses known as coronaviruses", "evidence": "Infections can occur indoors.\ncoronaviruses are a broad family of Viruses.", "einfo": {"ss": [0.62, 0.78], "cs": [1.0], "pv": [[], []], "uv": [["distances particularly indoors"], ["known as coronaviruses"]]}, "hf": 0}
{"context": "However infection can occur over longer distances particularly indoors\n Cause SARS\u2011CoV\u20112 belongs to the broad family of viruses known as coronaviruses\nIt is a positive-sense single-stranded RNA +ssRNA virus with a single linear RNA segment", "evidence": "Infections can occur indoors.\ncoronaviruses are a broad family of Viruses.\nThere is a positive-sense single-strandedRNA +ssRNA virus.", "einfo": {"ss": [0.62, 0.78, 0.75], "cs": [1.0], "pv": [[], [], ["positive-sense single-stranded RNA"]], "uv": [["distances particularly indoors"], ["known as coronaviruses"], []]}, "hf": 0}
{"context": "It is a positive-sense single-stranded RNA +ssRNA virus with a single linear RNA segment\nCoronaviruses infect humans other mammals including livestock and companion animals and avian species\nHuman coronaviruses are capable of causing illnesses ranging from the common cold to more severe diseases such as Middle East respiratory syndrome MERS fatality rate \u224834%\nSARS-CoV-2 is the seventh known coronavirus to infect people after 229E NL63 OC43 HKU1 MERS-CoV and the original SARS-CoV", "evidence": "There is a positive-sense single-strandedRNA +ssRNA virus.\nHumans and other mammals are susceptible to coronaviruses.\nThe human coronaviruses are capable of causing illnesses ranging from the common cold to more severe diseases.\nAfter 229E NL63 OC43 HKU1 and the original SARS-CoV, there are now seven known coronaviruses to affect people.", "einfo": {"ss": [0.75, 0.18, 0.2, 0.51], "cs": [1.0], "pv": [["positive-sense single-stranded RNA"], [], [], []], "uv": [[], ["Coronaviruses infect humans", "mammals including livestock", "livestock and companion"], ["East respiratory syndrome", "respiratory syndrome MERS", "Middle East respiratory", "syndrome MERS fatality"], ["infect people", "seventh known coronavirus"]]}, "hf": 0}
{"context": "Human coronaviruses are capable of causing illnesses ranging from the common cold to more severe diseases such as Middle East respiratory syndrome MERS fatality rate \u224834%\nSARS-CoV-2 is the seventh known coronavirus to infect people after 229E NL63 OC43 HKU1 MERS-CoV and the original SARS-CoV\n Diagnosis The standard method of testing for presence of SARS-CoV-2 is a nucleic acid test which detects the presence of viral RNA fragments\nAs these tests detect RNA but not infectious virus its ability to determine duration of infectivity of patients is limited", "evidence": "The human coronaviruses are capable of causing illnesses ranging from the common cold to more severe diseases.\nAfter 229E NL63 OC43 HKU1 and the original SARS-CoV, there are now seven known coronaviruses to affect people.\nA nucleic acid test is the standard method for testing for the presence of the disease.\nThe ability to determine the duration ofinfecting patients is limited by the fact that these tests do not detect infectious virus.", "einfo": {"ss": [0.2, 0.51, 0.62, 0.71], "cs": [1.0], "pv": [[], [], ["method of testing"], ["infectious virus", "determine duration"]], "uv": [["East respiratory syndrome", "respiratory syndrome MERS", "Middle East respiratory", "syndrome MERS fatality"], ["infect people", "seventh known coronavirus"], ["Diagnosis The standard"], ["duration of infectivity"]]}, "hf": 0}
{"context": "SARS-CoV-2 is the seventh known coronavirus to infect people after 229E NL63 OC43 HKU1 MERS-CoV and the original SARS-CoV\n Diagnosis The standard method of testing for presence of SARS-CoV-2 is a nucleic acid test which detects the presence of viral RNA fragments\nAs these tests detect RNA but not infectious virus its ability to determine duration of infectivity of patients is limited\nThe test is typically done on respiratory samples obtained by a nasopharyngeal swab; however a nasal swab or sputum sample may also be used", "evidence": "After 229E NL63 OC43 HKU1 and the original SARS-CoV, there are now seven known coronaviruses to affect people.\nA nucleic acid test is the standard method for testing for the presence of the disease.\nThe ability to determine the duration ofinfecting patients is limited by the fact that these tests do not detect infectious virus.\nThe test can be done on a respiratory sample obtained from a nasopharyngeal swab or a sputum sample.", "einfo": {"ss": [0.51, 0.62, 0.71, 0.5], "cs": [1.0], "pv": [[], ["method of testing"], ["infectious virus", "determine duration"], ["sputum sample may", "typically done"]], "uv": [["infect people", "seventh known coronavirus"], ["Diagnosis The standard"], ["duration of infectivity"], ["test is typically", "done on respiratory"]]}, "hf": 0}
{"context": "Diagnosis The standard method of testing for presence of SARS-CoV-2 is a nucleic acid test which detects the presence of viral RNA fragments\nAs these tests detect RNA but not infectious virus its ability to determine duration of infectivity of patients is limited\nThe test is typically done on respiratory samples obtained by a nasopharyngeal swab; however a nasal swab or sputum sample may also be used\nThe WHO has published several testing protocols for the disease", "evidence": "A nucleic acid test is the standard method for testing for the presence of the disease.\nThe ability to determine the duration ofinfecting patients is limited by the fact that these tests do not detect infectious virus.\nThe test can be done on a respiratory sample obtained from a nasopharyngeal swab or a sputum sample.\nSeveral testing protocols have been published by the World Health Organization.", "einfo": {"ss": [0.62, 0.71, 0.5, 0.5], "cs": [1.0], "pv": [["method of testing"], ["infectious virus", "determine duration"], ["sputum sample may", "typically done"], []], "uv": [["Diagnosis The standard"], ["duration of infectivity"], ["test is typically", "done on respiratory"], ["published several testing"]]}, "hf": 0}
{"context": "The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however a nasal swab or sputum sample may also be used\nThe WHO has published several testing protocols for the disease\n Prevention Preventive measures to reduce the chances of infection include getting vaccinated staying at home or spending more time outdoors avoiding crowded places keeping distance from others wearing a mask in public ventilating indoor spaces managing potential exposure durations washing hands with soap and water often and for at least twenty seconds practising good respiratory hygiene and avoiding touching the eyes nose or mouth with unwashed hands", "evidence": "The test can be done on a respiratory sample obtained from a nasopharyngeal swab or a sputum sample.\nSeveral testing protocols have been published by the World Health Organization.\nStaying at home, spending more time outdoors, wearing a mask in public, washing hands often, and practicing good respiratory hygiene are some of the preventive measures.", "einfo": {"ss": [0.5, 0.5, 0.03], "cs": [1.0], "pv": [["sputum sample may", "typically done"], [], []], "uv": [["test is typically", "done on respiratory"], ["published several testing"], ["public ventilating indoor", "Prevention Preventive measures", "include getting vaccinated", "getting vaccinated staying", "infection include getting", "ventilating indoor spaces", "spaces managing potential", "places keeping distance"]]}, "hf": 0}
{"context": "The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however a nasal swab or sputum sample may also be used\nThe WHO has published several testing protocols for the disease\n Prevention Preventive measures to reduce the chances of infection include getting vaccinated staying at home or spending more time outdoors avoiding crowded places keeping distance from others wearing a mask in public ventilating indoor spaces managing potential exposure durations washing hands with soap and water often and for at least twenty seconds practising good respiratory hygiene and avoiding touching the eyes nose or mouth with unwashed hands\nThose diagnosed with COVID-19 or who believe they may be infected are advised by healthcare authorities to stay home except to get medical care call ahead before visiting a healthcare provider wear a face mask before entering the healthcare providers office and when in any room or vehicle with another person cover coughs and sneezes with a tissue regularly wash hands with soap and water and avoid sharing personal household items", "evidence": "The test can be done on a respiratory sample obtained from a nasopharyngeal swab or a sputum sample.\nSeveral testing protocols have been published by the World Health Organization.\nStaying at home, spending more time outdoors, wearing a mask in public, washing hands often, and practicing good respiratory hygiene are some of the preventive measures.\nThose who have been diagnosed with COVID-19 are advised to stay home unless they need to go to a healthcare provider and wear a face mask.", "einfo": {"ss": [0.5, 0.5, 0.03, 0.07], "cs": [1.0], "pv": [["sputum sample may", "typically done"], [], [], ["stay home except"]], "uv": [["test is typically", "done on respiratory"], ["published several testing"], ["public ventilating indoor", "Prevention Preventive measures", "include getting vaccinated", "getting vaccinated staying", "infection include getting", "ventilating indoor spaces", "spaces managing potential", "places keeping distance"], ["personal household items", "avoid sharing personal", "tissue regularly wash", "another person cover", "regularly wash hands", "person cover coughs"]]}, "hf": 0}
{"context": "Those diagnosed with COVID-19 or who believe they may be infected are advised by healthcare authorities to stay home except to get medical care call ahead before visiting a healthcare provider wear a face mask before entering the healthcare providers office and when in any room or vehicle with another person cover coughs and sneezes with a tissue regularly wash hands with soap and water and avoid sharing personal household items\n Vaccines A COVID-19 vaccine is intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 SARS\u2011CoV\u20112 the virus that causes coronavirus disease 2019 COVID-19\nPrior to the COVID-19 pandemic an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome SARS and Middle East respiratory syndrome MERS\nThis knowledge accelerated the development of various vaccine platforms during early 2020", "evidence": "Those who have been diagnosed with COVID-19 are advised to stay home unless they need to go to a healthcare provider and wear a face mask.\nThe COVID-19 vaccine is intended to provide acquired immunity against coronaviruses.\nThere was an established body of knowledge about the structure and function of coronaviruses prior to the COVID-19 pandemic.\nThe development of vaccine platforms was accelerated because of this knowledge.", "einfo": {"ss": [0.07, 0.62, 0.07, 0.47], "cs": [1.0], "pv": [["stay home except"], ["immunity against severe"], [], ["various vaccine platforms", "development of various", "knowledge accelerated"]], "uv": [["personal household items", "avoid sharing personal", "tissue regularly wash", "another person cover", "regularly wash hands", "person cover coughs"], ["respiratory syndrome coronavirus"], ["coronaviruses causing diseases", "SARS and Middle", "acute respiratory syndrome", "respiratory syndrome MERS", "East respiratory syndrome", "severe acute respiratory"], ["accelerated the development"]]}, "hf": 0}
{"context": "Vaccines A COVID-19 vaccine is intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 SARS\u2011CoV\u20112 the virus that causes coronavirus disease 2019 COVID-19\nPrior to the COVID-19 pandemic an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome SARS and Middle East respiratory syndrome MERS\nThis knowledge accelerated the development of various vaccine platforms during early 2020", "evidence": "The COVID-19 vaccine is intended to provide acquired immunity against coronaviruses.\nThere was an established body of knowledge about the structure and function of coronaviruses prior to the COVID-19 pandemic.\nThe development of vaccine platforms was accelerated because of this knowledge.", "einfo": {"ss": [0.62, 0.07, 0.47], "cs": [1.0], "pv": [["immunity against severe"], [], ["various vaccine platforms", "development of various", "knowledge accelerated"]], "uv": [["respiratory syndrome coronavirus"], ["coronaviruses causing diseases", "SARS and Middle", "acute respiratory syndrome", "respiratory syndrome MERS", "East respiratory syndrome", "severe acute respiratory"], ["accelerated the development"]]}, "hf": 0}
{"context": "This knowledge accelerated the development of various vaccine platforms during early 2020\nThe initial focus of SARS-CoV-2 vaccines was on preventing symptomatic and severe illness\nThe COVID-19 vaccines are widely credited for their role in reducing the severity and death caused by COVID-19", "evidence": "The development of vaccine platforms was accelerated because of this knowledge.\nThe initial focus was on preventing illness.\nThe severity and death caused by COVID-19 have been reduced by the COVID-19 vaccines.", "einfo": {"ss": [0.47, 0.67, 0.78], "cs": [1.0], "pv": [["various vaccine platforms", "development of various", "knowledge accelerated"], [], []], "uv": [["accelerated the development"], ["preventing symptomatic"], ["vaccines are widely"]]}, "hf": 0}
{"context": "The COVID-19 vaccines are widely credited for their role in reducing the severity and death caused by COVID-19\nAs of March 2023 more than 55 billion people had received one or more doses 118 billion in total in over 197 countries\nThe Oxford-AstraZeneca vaccine was the most widely used\nAccording to a June 2022 study COVID-19 vaccines prevented an additional 144 million to 198 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021", "evidence": "The severity and death caused by COVID-19 have been reduced by the COVID-19 vaccines.\nMore than 55 billion people had received one or more doses by the end of March.\nThe most popular vaccine was the Oxford-AstraZeneca.\nMore than 200 million deaths were prevented by the COVID-19 vaccines from December 2020 to December 2021.", "einfo": {"ss": [0.78, 0.83, 0.33, 0.53], "cs": [1.0], "pv": [[], [], ["Oxford-AstraZeneca vaccine"], []], "uv": [["vaccines are widely"], ["March"], ["widely used"], ["December", "vaccines prevented"]]}, "hf": 0}
{"context": "As of March 2023 more than 55 billion people had received one or more doses 118 billion in total in over 197 countries\nThe Oxford-AstraZeneca vaccine was the most widely used\nAccording to a June 2022 study COVID-19 vaccines prevented an additional 144 million to 198 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021", "evidence": "More than 55 billion people had received one or more doses by the end of March.\nThe most popular vaccine was the Oxford-AstraZeneca.\nMore than 200 million deaths were prevented by the COVID-19 vaccines from December 2020 to December 2021.", "einfo": {"ss": [0.83, 0.33, 0.53], "cs": [1.0], "pv": [[], ["Oxford-AstraZeneca vaccine"], []], "uv": [["March"], ["widely used"], ["December", "vaccines prevented"]]}, "hf": 0}
{"context": "According to a June 2022 study COVID-19 vaccines prevented an additional 144 million to 198 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021\nOn 8 November 2022 the first recombinant protein-based COVID-19 vaccine Novavaxs booster Nuvaxovid was authorised for use in adults in the United Kingdom\nIt has subsequently received endorsement/authorisation from the WHO US European Union and Australia\nOn 12 November 2022 the WHO released its Global Vaccine Market Report", "evidence": "More than 200 million deaths were prevented by the COVID-19 vaccines from December 2020 to December 2021.\nNovavaxs booster Nuvaxovid was approved for use in adults in the United Kingdom on November 8, 2022.\nThe WHO US European Union and Australia have endorsed it.\nThe Global Vaccine Market Report was released by the WHO.", "einfo": {"ss": [0.53, 0.62, 0.67, 1.0], "cs": [1.0], "pv": [[], ["Nuvaxovid was authorised"], [], []], "uv": [["December", "vaccines prevented"], ["first recombinant protein-based"], ["subsequently received endorsement"], []]}, "hf": 0}
{"context": "On 8 November 2022 the first recombinant protein-based COVID-19 vaccine Novavaxs booster Nuvaxovid was authorised for use in adults in the United Kingdom\nIt has subsequently received endorsement/authorisation from the WHO US European Union and Australia\nOn 12 November 2022 the WHO released its Global Vaccine Market Report\nThe report indicated that inequitable distribution is not unique to COVID-19 vaccines; countries that are not economically strong struggle to obtain vaccines", "evidence": "Novavaxs booster Nuvaxovid was approved for use in adults in the United Kingdom on November 8, 2022.\nThe WHO US European Union and Australia have endorsed it.\nThe Global Vaccine Market Report was released by the WHO.\nAccording to the report, inequitable distribution is not unique to COVID-19 vaccines.", "einfo": {"ss": [0.62, 0.67, 1.0, 0.4], "cs": [1.0], "pv": [["Nuvaxovid was authorised"], [], [], ["obtain vaccines", "report indicated"]], "uv": [["first recombinant protein-based"], ["subsequently received endorsement"], [], ["economically strong struggle", "indicated that inequitable"]]}, "hf": 0}
{"context": "It has subsequently received endorsement/authorisation from the WHO US European Union and Australia\nOn 12 November 2022 the WHO released its Global Vaccine Market Report\nThe report indicated that inequitable distribution is not unique to COVID-19 vaccines; countries that are not economically strong struggle to obtain vaccines\nOn 14 November 2022 the first inhalable vaccine was introduced developed by Chinese biopharmaceutical company CanSino Biologics in the city of Shanghai China", "evidence": "The WHO US European Union and Australia have endorsed it.\nThe Global Vaccine Market Report was released by the WHO.\nAccording to the report, inequitable distribution is not unique to COVID-19 vaccines.\nThe first inhalable vaccine was introduced by CanSino Biologics on November 14, 2022.", "einfo": {"ss": [0.67, 1.0, 0.4, 0.42], "cs": [1.0], "pv": [[], [], ["obtain vaccines", "report indicated"], ["company CanSino Biologics"]], "uv": [["subsequently received endorsement"], [], ["economically strong struggle", "indicated that inequitable"], ["Chinese biopharmaceutical company", "biopharmaceutical company CanSino"]]}, "hf": 0}
{"context": "It has subsequently received endorsement/authorisation from the WHO US European Union and Australia\nOn 12 November 2022 the WHO released its Global Vaccine Market Report\nThe report indicated that inequitable distribution is not unique to COVID-19 vaccines; countries that are not economically strong struggle to obtain vaccines\nOn 14 November 2022 the first inhalable vaccine was introduced developed by Chinese biopharmaceutical company CanSino Biologics in the city of Shanghai China", "evidence": "The WHO US European Union and Australia have endorsed it.\nThe Global Vaccine Market Report was released by the WHO.\nAccording to the report, inequitable distribution is not unique to COVID-19 vaccines.\nThe first inhalable vaccine was introduced by CanSino Biologics on November 14, 2022.", "einfo": {"ss": [0.67, 1.0, 0.4, 0.42], "cs": [1.0], "pv": [[], [], ["obtain vaccines", "report indicated"], ["company CanSino Biologics"]], "uv": [["subsequently received endorsement"], [], ["economically strong struggle", "indicated that inequitable"], ["Chinese biopharmaceutical company", "biopharmaceutical company CanSino"]]}, "hf": 0}
{"context": "The report indicated that inequitable distribution is not unique to COVID-19 vaccines; countries that are not economically strong struggle to obtain vaccines\nOn 14 November 2022 the first inhalable vaccine was introduced developed by Chinese biopharmaceutical company CanSino Biologics in the city of Shanghai China", "evidence": "According to the report, inequitable distribution is not unique to COVID-19 vaccines.\nThe first inhalable vaccine was introduced by CanSino Biologics on November 14, 2022.", "einfo": {"ss": [0.4, 0.42], "cs": [1.0], "pv": [["obtain vaccines", "report indicated"], ["company CanSino Biologics"]], "uv": [["economically strong struggle", "indicated that inequitable"], ["Chinese biopharmaceutical company", "biopharmaceutical company CanSino"]]}, "hf": 0}
{"context": "On 14 November 2022 the first inhalable vaccine was introduced developed by Chinese biopharmaceutical company CanSino Biologics in the city of Shanghai China\n Treatment For the first two years of the pandemic no specific and effective treatment or cure was available", "evidence": "The first inhalable vaccine was introduced by CanSino Biologics on November 14, 2022.\nThere was no specific and effective treatment or cure for the first two years of the epidemic.", "einfo": {"ss": [0.42, 0.8], "cs": [1.0], "pv": [["company CanSino Biologics"], []], "uv": [["Chinese biopharmaceutical company", "biopharmaceutical company CanSino"], ["pandemic no specific"]]}, "hf": 0}
{"context": "Treatment For the first two years of the pandemic no specific and effective treatment or cure was available\nIn 2021 the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP approved the oral antiviral protease inhibitor Paxlovid nirmatrelvir plus the HIV antiviral ritonavir to treat adult patients\nFDA later gave it an EUA", "evidence": "There was no specific and effective treatment or cure for the first two years of the epidemic.\nThe European Medicines Agency's Committee for Medicinal Products for Human Use approved Paxlovid nirmatrelvir and the HIV antiviral ritonavir to treat adult patients.\nIt was given an EUA by the FDA.", "einfo": {"ss": [0.8, 0.6, 0.33], "cs": [1.0], "pv": [[], ["inhibitor Paxlovid nirmatrelvir", "European Medicines Agencys", "Use CHMP approved", "Human Use CHMP"], []], "uv": [["pandemic no specific"], ["Medicines Agencys EMA"], ["EUA", "FDA later gave"]]}, "hf": 0}
{"context": "FDA later gave it an EUA\nMost cases of COVID-19 are mild\nIn these supportive care includes medication such as paracetamol or NSAIDs to relieve symptoms fever body aches cough adequate intake of oral fluids and rest\nGood personal hygiene and a healthy diet are also recommended", "evidence": "It was given an EUA by the FDA.\nMild cases of COVID-19 are what most of them are.\nAdequate intake of oral fluids and rest is included in supportive care.\nA healthy diet and good personal hygiene are also important.", "einfo": {"ss": [0.33, 0.5, 0.36, 0.63], "cs": [1.0], "pv": [[], ["cases"], ["cough adequate intake", "supportive care includes"], []], "uv": [["EUA", "FDA later gave"], [], ["care includes medication", "relieve symptoms fever", "aches cough adequate", "symptoms fever body"], ["also recommended", "diet are also"]]}, "hf": 0}
{"context": "In these supportive care includes medication such as paracetamol or NSAIDs to relieve symptoms fever body aches cough adequate intake of oral fluids and rest\nGood personal hygiene and a healthy diet are also recommended\nSupportive care in severe cases includes treatment to relieve symptoms fluid therapy oxygen support and prone positioning and medications or devices to support other affected vital organs\nMore severe cases may need treatment in hospital\nIn those with low oxygen levels use of the glucocorticoid dexamethasone is recommended to reduce mortality", "evidence": "Adequate intake of oral fluids and rest is included in supportive care.\nA healthy diet and good personal hygiene are also important.\nIn severe cases, supportive care includes treatment to relieve symptoms such as fluid therapy oxygen support and prone positioning.\nIt is possible that more severe cases will need hospital treatment.\nThe use of dexamethasone is recommended for people with low oxygen levels.", "einfo": {"ss": [0.36, 0.63, 0.64, 0.56, 0.49], "cs": [1.0], "pv": [["cough adequate intake", "supportive care includes"], [], ["Supportive care", "severe cases includes", "cases includes treatment"], ["severe cases may", "treatment in hospital", "cases may need"], []], "uv": [["care includes medication", "relieve symptoms fever", "aches cough adequate", "symptoms fever body"], ["also recommended", "diet are also"], ["relieve symptoms fluid"], [], ["glucocorticoid dexamethasone", "recommended to reduce", "oxygen levels use"]]}, "hf": 0}
{"context": "Good personal hygiene and a healthy diet are also recommended\nSupportive care in severe cases includes treatment to relieve symptoms fluid therapy oxygen support and prone positioning and medications or devices to support other affected vital organs\nMore severe cases may need treatment in hospital", "evidence": "A healthy diet and good personal hygiene are also important.\nIn severe cases, supportive care includes treatment to relieve symptoms such as fluid therapy oxygen support and prone positioning.\nIt is possible that more severe cases will need hospital treatment.", "einfo": {"ss": [0.63, 0.64, 0.56], "cs": [1.0], "pv": [[], ["Supportive care", "severe cases includes", "cases includes treatment"], ["severe cases may", "treatment in hospital", "cases may need"]], "uv": [["also recommended", "diet are also"], ["relieve symptoms fluid"], []]}, "hf": 0}
{"context": "Supportive care in severe cases includes treatment to relieve symptoms fluid therapy oxygen support and prone positioning and medications or devices to support other affected vital organs\nMore severe cases may need treatment in hospital\nIn those with low oxygen levels use of the glucocorticoid dexamethasone is recommended to reduce mortality", "evidence": "In severe cases, supportive care includes treatment to relieve symptoms such as fluid therapy oxygen support and prone positioning.\nIt is possible that more severe cases will need hospital treatment.\nThe use of dexamethasone is recommended for people with low oxygen levels.", "einfo": {"ss": [0.64, 0.56, 0.49], "cs": [1.0], "pv": [["Supportive care", "severe cases includes", "cases includes treatment"], ["severe cases may", "treatment in hospital", "cases may need"], []], "uv": [["relieve symptoms fluid"], [], ["glucocorticoid dexamethasone", "recommended to reduce", "oxygen levels use"]]}, "hf": 0}
{"context": "In those with low oxygen levels use of the glucocorticoid dexamethasone is recommended to reduce mortality\nNoninvasive ventilation and ultimately admission to an intensive care unit for mechanical ventilation may be required to support breathing\nExtracorporeal membrane oxygenation ECMO has been used to address the issue of respiratory failure", "evidence": "The use of dexamethasone is recommended for people with low oxygen levels.\nRespiratory support may be required for admission to an intensive care unit.\nThe issue of respiratory failure has been addressed using extracorporeal membrane oxygenation.", "einfo": {"ss": [0.49, 0.62, 0.74], "cs": [1.0], "pv": [[], [], ["used to address"]], "uv": [["glucocorticoid dexamethasone", "recommended to reduce", "oxygen levels use"], ["support breathing", "ultimately admission"], ["membrane oxygenation ECMO"]]}, "hf": 0}
{"context": "In those with low oxygen levels use of the glucocorticoid dexamethasone is recommended to reduce mortality\nNoninvasive ventilation and ultimately admission to an intensive care unit for mechanical ventilation may be required to support breathing\nExtracorporeal membrane oxygenation ECMO has been used to address the issue of respiratory failure", "evidence": "The use of dexamethasone is recommended for people with low oxygen levels.\nRespiratory support may be required for admission to an intensive care unit.\nThe issue of respiratory failure has been addressed using extracorporeal membrane oxygenation.", "einfo": {"ss": [0.49, 0.62, 0.74], "cs": [1.0], "pv": [[], [], ["used to address"]], "uv": [["glucocorticoid dexamethasone", "recommended to reduce", "oxygen levels use"], ["support breathing", "ultimately admission"], ["membrane oxygenation ECMO"]]}, "hf": 0}
{"context": "Existing drugs such as hydroxychloroquine lopinavir/ritonavir and ivermectin are not recommended by US or European health authorities as there is no good evidence they have any useful effect\nThe antiviral remdesivir is available in the US Canada Australia and several other countries with varying restrictions; however it is not recommended for use with mechanical ventilation and is discouraged altogether by the WHO due to limited evidence of its efficacy", "evidence": "There is no good evidence that existing drugs such as ivermectin have any useful effect.\nIn the US, Canada, Australia, and several other countries it is available, however it is not recommended for use with mechanical ventilation due to limited evidence of its efficacy.", "einfo": {"ss": [0.75, 0.52], "cs": [1.0], "pv": [[], ["mechanical ventilation", "Canada Australia"]], "uv": [["hydroxychloroquine lopinavir"], ["remdesivir is available", "countries with varying", "Australia and several"]]}, "hf": 0}
{"context": "Prognosis The severity of COVID-19 varies\nIt may take a mild course with few or no symptoms resembling other common upper respiratory diseases such as the common cold", "evidence": "The severity of COVID-19 depends on the prognosis.\nIt is possible to take a mild course with few or no symptoms similar to other upper respiratory diseases.", "einfo": {"ss": [0.17, 0.72], "cs": [1.0], "pv": [[], []], "uv": [["Prognosis The severity", "varies"], ["symptoms resembling", "may take"]]}, "hf": 0}
{"context": "In 3\u20134% of cases 74% for those over age 65 symptoms are severe enough to cause hospitalisation\nMild cases typically recover within two weeks while those with severe or critical diseases may take three to six weeks to recover", "evidence": "More than 70% of those over the age of 65 have symptoms that are severe enough to be hospitalized.\nMild cases usually recover within two weeks, while those with severe or critical diseases can take up to six weeks to recover.", "einfo": {"ss": [0.58, 0.7], "cs": [1.0], "pv": [[], ["typically recover within", "cases typically recover", "Mild cases typically"]], "uv": [["symptoms are severe", "cause hospitalisation"], []]}, "hf": 0}
{"context": "Mild cases typically recover within two weeks while those with severe or critical diseases may take three to six weeks to recover\nAmong those who have died the time from symptom onset to death has ranged from two to eight weeks\nProlonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID-19 and with a transfer to intensive care units ICU", "evidence": "Mild cases usually recover within two weeks, while those with severe or critical diseases can take up to six weeks to recover.\nThe time from symptom to death ranged from 2 to 8 weeks.\nProlonged prothrombin time and elevated C-reactiveprotein levels on admission to the hospital are associated with a severe course of COVID-19.", "einfo": {"ss": [0.7, 0.67, 0.67], "cs": [1.0], "pv": [["typically recover within", "cases typically recover", "Mild cases typically"], ["death has ranged", "onset to death", "eight weeks"], []], "uv": [[], [], ["elevated C-reactive protein"]]}, "hf": 0}
{"context": "Mild cases typically recover within two weeks while those with severe or critical diseases may take three to six weeks to recover\nAmong those who have died the time from symptom onset to death has ranged from two to eight weeks\nProlonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID-19 and with a transfer to intensive care units ICU\nBetween 5% and 50% of COVID-19 patients experience long COVID a condition characterised by long-term consequences persisting after the typical convalescence period of the disease\nThe most commonly reported clinical presentations are fatigue and memory problems as well as malaise headaches shortness of breath loss of smell muscle weakness low fever and cognitive dysfunction", "evidence": "Mild cases usually recover within two weeks, while those with severe or critical diseases can take up to six weeks to recover.\nThe time from symptom to death ranged from 2 to 8 weeks.\nProlonged prothrombin time and elevated C-reactiveprotein levels on admission to the hospital are associated with a severe course of COVID-19.\nLong COVID is a condition in which long-term consequences persist after the typical convalescence period of the disease.\nThe most common presentations are fatigue and memory problems as well as headaches and nausea.", "einfo": {"ss": [0.7, 0.67, 0.67, 0.89, 0.06], "cs": [1.0], "pv": [["typically recover within", "cases typically recover", "Mild cases typically"], ["death has ranged", "onset to death", "eight weeks"], [], ["experience long COVID"], []], "uv": [[], [], ["elevated C-reactive protein"], [], ["reported clinical presentations", "malaise headaches shortness", "commonly reported clinical", "smell muscle weakness", "cognitive dysfunction", "muscle weakness low", "weakness low fever"]]}, "hf": 0}
{"context": "Prolonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID-19 and with a transfer to intensive care units ICU\nBetween 5% and 50% of COVID-19 patients experience long COVID a condition characterised by long-term consequences persisting after the typical convalescence period of the disease", "evidence": "Prolonged prothrombin time and elevated C-reactiveprotein levels on admission to the hospital are associated with a severe course of COVID-19.\nLong COVID is a condition in which long-term consequences persist after the typical convalescence period of the disease.", "einfo": {"ss": [0.67, 0.89], "cs": [1.0], "pv": [[], ["experience long COVID"]], "uv": [["elevated C-reactive protein"], []]}, "hf": 0}
{"context": "Between 5% and 50% of COVID-19 patients experience long COVID a condition characterised by long-term consequences persisting after the typical convalescence period of the disease\nThe most commonly reported clinical presentations are fatigue and memory problems as well as malaise headaches shortness of breath loss of smell muscle weakness low fever and cognitive dysfunction", "evidence": "Long COVID is a condition in which long-term consequences persist after the typical convalescence period of the disease.\nThe most common presentations are fatigue and memory problems as well as headaches and nausea.", "einfo": {"ss": [0.89, 0.06], "cs": [1.0], "pv": [["experience long COVID"], []], "uv": [[], ["reported clinical presentations", "malaise headaches shortness", "commonly reported clinical", "smell muscle weakness", "cognitive dysfunction", "muscle weakness low", "weakness low fever"]]}, "hf": 0}
